

# Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the AGREE Conference

Q1 Q2 Q3 **Evan S. Dellon,<sup>1,\*</sup> Chris A. Liacouras,<sup>2,\*</sup> Javier Molina-Infante,<sup>3,\*</sup> Glenn T. Furuta,<sup>4,\*</sup>**

Jonathan M. Spergel,<sup>5</sup> Noam Zevit,<sup>6</sup> Stuart J. Spechler,<sup>7</sup> Stephen E. Attwood,<sup>8</sup> Alex Straumann,<sup>9</sup> Seema S. Aceves,<sup>10</sup> Jeffrey A. Alexander,<sup>11</sup> Dan Atkins,<sup>12</sup> Nicoleta C. Arva,<sup>13</sup> Carine Blanchard,<sup>14</sup> Peter A. Bonis,<sup>15</sup> Wendy M. Book,<sup>16</sup> Kelley E. Capocelli,<sup>17</sup> Mirna Chehade,<sup>18</sup> Edaire Cheng,<sup>19</sup> Margaret H. Collins,<sup>20</sup> Carla M. Davis,<sup>21</sup> Jorge A. Dias,<sup>22</sup> Carlo Di Lorenzo,<sup>23</sup> Ranjan Dohil,<sup>24</sup> Christophe Dupont,<sup>25</sup> Gary W. Falk,<sup>26</sup> Cristina T. Ferreira,<sup>27</sup> Adam Fox,<sup>28</sup> Nirmala P. Gonsalves,<sup>29</sup> Sandeep K. Gupta,<sup>30</sup> David A. Katzka,<sup>11</sup> Yoshikazu Kinoshita,<sup>31</sup> Calies Menard-Katcher,<sup>4</sup> Elynn Kodroff,<sup>32</sup> David C. Metz,<sup>26</sup> Stephan Miehke,<sup>33</sup> Amanda B. Muir,<sup>2</sup> Vincent A. Mukkada,<sup>34</sup> Simon Murch,<sup>35</sup> Samuel Nurko,<sup>36</sup> Yoshikazu Ohtsuka,<sup>37</sup> Rok Orel,<sup>38</sup> Alexandra Papadopoulou,<sup>39</sup> Kathryn A. Peterson,<sup>40</sup> Hamish Philpott,<sup>41</sup> Philip E. Putnam,<sup>34</sup> Joel E. Richter,<sup>42</sup> Rachel Rosen,<sup>43</sup> Marc E. Rothenberg,<sup>44</sup> Alain Schoepfer,<sup>45</sup> Melissa M. Scott,<sup>46</sup> Neil Shah,<sup>47</sup> Javed Sheikh,<sup>48</sup> Rhonda F. Souza,<sup>7</sup> Mary J. Strobel,<sup>16</sup> Nicholas J. Talley,<sup>49</sup> Michael F. Vaezi,<sup>50</sup> Yvan Vandenplas,<sup>51</sup> Mario C. Vieira,<sup>52</sup> Marjorie M. Walker,<sup>53</sup> Joshua B. Wechsler,<sup>54</sup> Barry K. Wershil,<sup>54</sup> Ting Wen,<sup>44</sup> Guang-Yu Yang,<sup>55</sup> Ikuo Hirano,<sup>29,§</sup> and Albert J. Bredenoord<sup>56,§</sup>

<sup>1</sup>Center for Esophageal Diseases and Swallowing, Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; <sup>2</sup>Center for Pediatric Eosinophilic Diseases, Division of Gastroenterology and Hepatology & Nutrition, Children's Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania; <sup>3</sup>Department of Gastroenterology, Hospital Universitario San Pedro de Alcántara, Cáceres, Spain and Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain; <sup>4</sup>Digestive Health Institute, Children's Hospital Colorado, Aurora, Colorado and Gastrointestinal Eosinophilic Diseases Program, University of Colorado School of Medicine, Aurora, Colorado; <sup>5</sup>Center for Pediatric Eosinophilic Diseases, Division of Allergy-Immunology, The Children's Hospital of Philadelphia, Perelman School of Medicine at University of Pennsylvania, Philadelphia, Pennsylvania; <sup>6</sup>Institute of Gastroenterology, Nutrition and Liver Diseases, Schneider Children's Medical Center of Israel, Petach Tikva, and Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel; <sup>7</sup>Center for Esophageal Diseases, Baylor University Medical Center and Center for Esophageal Research, Baylor Scott & White Research Institute, Dallas, Texas; <sup>8</sup>Department of Health Services Research, Durham University, Durham, UK; <sup>9</sup>Swiss EoE Research Network, Olten, Switzerland; <sup>10</sup>Division of Allergy, Immunology, Departments of Pediatrics and Medicine, University of California–San Diego and Rady Children's Hospital, San Diego, La Jolla, California; <sup>11</sup>Division of Gastroenterology, Mayo Clinic, Rochester, Minnesota; <sup>12</sup>Allergy & Immunology Section, Children's Hospital Colorado and Gastrointestinal Eosinophilic Diseases Program, University of Colorado School of Medicine, Aurora, Colorado; <sup>13</sup>Department of Pathology and Laboratory Medicine, Ann & Robert H. Lurie Children's Hospital of Chicago, Feinberg School of Medicine, Northwestern University, Chicago, Illinois; <sup>14</sup>Institute of Nutritional Science, Nestlé Research Center, ■■■, Switzerland; <sup>15</sup>Division of Gastroenterology, Tufts University School of Medicine, Boston, Massachusetts; <sup>16</sup>American Partnership for Eosinophilic Disorders, Atlanta, Georgia; <sup>17</sup>Department of Pediatric Pathology, Children's Hospital Colorado, Aurora, Colorado; <sup>18</sup>Mount Sinai Center for Eosinophilic Disorders, Icahn School of Medicine at Mount Sinai, New York, New York; <sup>19</sup>Departments of Pediatrics and Internal Medicine, Children's Medical Center, University of Texas Southwestern Medical Center, Dallas, Texas; <sup>20</sup>Division of Pathology and Laboratory Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio; <sup>21</sup>Allergy and Immunology Section of the Department of Pediatrics, Baylor College of Medicine, Texas Children's Hospital, Houston, Texas; <sup>22</sup>Pediatric Gastroenterology, Centro Hospitalar S. João, Porto, Portugal; <sup>23</sup>Division of Gastroenterology and Hepatology & Nutrition, Nationwide Children's Hospital, The Ohio State University, Columbus, Ohio; <sup>24</sup>Division of Gastroenterology and Hepatology, University of California–San Diego, Rady Children's Hospital, San Diego, California; <sup>25</sup>Necker Hospital, Paris-Descartes University, Paris, France; <sup>26</sup>Division of Gastroenterology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania; <sup>27</sup>Federal University of Health Sciences of Porto Alegre, Hospital Santo Antônio, ■■■, ■■■; <sup>28</sup>Department of Paediatric Allergy, Guy's & St Thomas' Hospitals NHS Foundation Trust, London, UK; <sup>29</sup>Division of Gastroenterology and Hepatology, Northwestern University–Feinberg School of Medicine, Chicago, Illinois; <sup>30</sup>Division of Pediatric Gastroenterology, Hepatology and Nutrition, Children's Hospital of Illinois, University of Illinois, Peoria, Illinois; <sup>31</sup>Department of Gastroenterology and Hepatology, Shimane University School of Medicine, Izumo, Japan; <sup>32</sup>Campaign Urging Research for Eosinophilic Diseases, Lincolnshire, Illinois; <sup>33</sup>Centre for Digestive Diseases, Internal Medicine Center, Eppendorf, Hamburg, Germany; <sup>34</sup>Division of Gastroenterology, Hepatology, and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio; <sup>35</sup>Department of Paediatrics, University Hospital Coventry & Warwickshire, Coventry, UK; <sup>36</sup>Center for Motility and Functional Gastrointestinal Disorders, Boston Children's Hospital, Boston, Massachusetts; <sup>37</sup>Department of Pediatrics and Adolescent Medicine, Juntendo University Graduate School



**Table 1.** Rationale for Changing the EoE Diagnostic Criteria and Removing the PPI Trial

Rationale	Comment
Similarities between EoE and PPI-REE	EoE and PPI-REE share similar clinical, endoscopic, histologic, immunologic, and molecular features before PPI treatment, suggesting that distinguishing these entities with a medication trial is artificial and that PPIs are better positioned as a treatment for EoE.
EoE and GERD are not necessarily mutually exclusive	An initial rationale for the PPI trial was to distinguish EoE from GERD, but it is now known that these conditions have a complex relationship and are not necessarily mutually exclusive.
Lack of a criterion standard for GERD diagnosis	Without a definitive method for defining GERD, no single test (including a PPI trial) can exclude the presence of GERD.
Novel mechanisms of action of PPIs to explain response of eosinophilia	Mechanisms that support PPIs as a treatment for EoE and esophageal eosinophilia include acid-independent anti-inflammatory/anti-eosinophil activity and reversal of epithelial permeability.
Observation that PPI-REE could also respond to classic EoE treatments	Patients with PPI-REE can also have a response to dietary elimination or topical steroid therapy, further blurring the line between EoE and PPI-REE.
Concern about using a treatment response to define a disease	Few diseases are primarily defined by response to treatment, and doing so limits potential treatment options for patients with EoE and esophageal eosinophilia.

GERD.<sup>5-10</sup> Because of this, diagnostic guidelines published in 2011, 2013, and 2014 defined a new condition termed *PPI-responsive esophageal eosinophilia* (PPI-REE).<sup>4,11,12</sup> Patients with PPI-REE had symptoms of esophageal dysfunction and  $\geq 15$  eos/hpf on esophageal biopsy but improvement or resolution of symptoms and eosinophilia after a high-dose PPI trial. In these guidelines, PPI-REE was not well understood, but EoE and GERD were still believed to be 2 distinct conditions.<sup>13</sup>

However, an evolving body of research suggested that EoE and GERD were not necessarily mutually exclusive and instead shared a complex relationship (they can coexist: EoE can lead to secondary reflux due to decreased esophageal compliance or dysmotility, and GERD can lead to decreased epithelial barrier integrity, allowing antigen exposure and subsequent eosinophilia).<sup>14</sup> In addition, a number of studies examined the clinical, endoscopic, and histologic features at baseline (before a PPI trial) of both EoE and PPI-REE and found no conclusive factors could distinguish the 2 conditions.<sup>6-10,15,16</sup> Concomitant atopic conditions were common in EoE and PPI-REE,<sup>6,8-10</sup> allergic and inflammatory factors were found to be elevated in both,<sup>17-19</sup> and RNA expression profiles were largely similar between the 2 conditions (and distinct from GERD), with normalization after topical steroid treatment or dietary elimination, although some differences existed.<sup>20,21</sup> In addition, case reports of PPI-REE patients showed that after stopping PPI treatment, patient symptoms and esophageal eosinophilia recurred and subsequently responded to classical EoE treatments of diet restriction or topical steroids.<sup>22,23</sup> Finally, several potential non-acid-mediated mechanisms were described that could explain the PPI response in PPI-REE.<sup>24-26</sup> Thus, PPI-REE emerged as subtype of EoE in some patients, and a controversy developed over whether EoE and PPI-REE were in fact the same condition, whether PPI-REE was a food allergy-associated disease, whether PPIs should be considered as EoE treatment, and

whether a PPI trial should be removed from the diagnostic guideline.<sup>27,28</sup> However, taken together, these new research advances provided a strong rationale for the consideration of removing the PPI trial from the EoE diagnostic algorithm (Table 1).

In favor of the continued inclusion of the PPI trial were the facts that it potentially reduces the number of endoscopies required, helps address concomitant GERD, and provides a stepwise approach for EoE diagnosis. In favor of eliminating the use of a PPI trial was the fact that it permits the ability to discuss a range of therapies (eg, some used for classic EoE) without committing patients to a PPI from the outset. It would also help achieve broader enrollment in clinical trials, allow treatment of esophageal eosinophilia with PPIs regardless of the underlying cause, and remove medication response as a diagnostic criterion. A new European EoE guideline, published in 2017,<sup>29</sup> suggested that PPI-REE and EoE were on the same spectrum and that PPIs could be considered a treatment for EoE. However, an operationalized approach to EoE diagnosis was not presented. To address these issues, we convened the AGREE (A Working Group on PPI-REE) Conference, which was held on May 6, 2017, in Chicago, IL.

## Methods

### Scope and Purpose

We conducted a consensus-building process consistent with standards described in the Appraisal of Guidelines for Research and Evaluation II.<sup>30</sup> Thought leaders in gastroenterology, allergy, and pathology were divided into teams to review the pertinent literature to address 3 questions that would inform the overall objective of developing new consensus diagnostic criteria for EoE:

1. What is the evidence to support the use of PPIs for suspected EoE in children, adolescents, and adults?

2. What mechanisms could explain resolution of esophageal eosinophilia by PPIs?
3. What are the sensitivity and specificity of diagnostic tests for GERD?

### Methods of Review

**Stakeholder Involvement.** This proceeding was developed by pediatric and adult physicians and researchers from gastroenterology, allergy, and pathology subspecialties with extensive experience in clinical care and research activities. There were 66 participants were from 14 countries. In addition, views and preferences of patients have been sought by soliciting input from patient advocacy groups including American Partnership for Eosinophilic Disorders (APFED), Campaign Urging Research for Eosinophilic Disease (CURED), and Eosinophilic Family Coalition (EFC). The patient advocacy groups raised important issues related to treatment response, epidemiology, clinical approach to borderline cases, and need for education about updated diagnostic criteria. The target users are primary care physicians involved in referring patients for consultation and specialty care physicians who provide initial and longitudinal care for patients affected by EoE.

**Rigor of Development.** We searched the PubMed database for relevant publications from inception (1966) through December 2016. Search terms included *eosinophilic esophagitis*, *esophageal eosinophilia*, *proton pump inhibitor responsive esophageal eosinophilia*. There was no language restriction. A separate search was conducted for each key question addressed in the review, using terms that addressed the specific question. We included studies of any design that reported 1 or more patients of any age with esophageal eosinophilia who were treated with PPIs. We excluded review articles and did not include reports with <5 cases in our PPI response summary ranges. Bibliographies of retrieved studies were reviewed to identify additional relevant citations. In addition, domain experts reviewed the retrieved citations to ensure that there were no relevant omissions. Although a formal quality assessment was not performed, limitations of the evidence (eg, retrospective design, small sample size, non-standardized outcome metrics, sources of bias) were assessed by each team. We acknowledge that use of a single search engine and lack of a formal quality assessment tool are potential methodologic limitations.

Between January 2017 and April 2017, each topic was discussed by a team of physicians (8–12 per topic) with expertise in identified topics. Literature was distributed electronically to each team, assessed with respect to ability to address the proposed question, and then discussed electronically and by teleconference (2–4 per team). Over this series of teleconferences, initial consensus was achieved (100% agreement of teleconference participants) after ongoing discussions regarding the answer to the assigned question. On May 5, 2017, an 8-hour face-to-face meeting with 43 of the AGREE members was held, during which each team presented their findings for the original questions and discussion ensued to build final consensus. Agreement was assessed by a system of hand votes on the proposed questions, and there was 100% agreement of meeting attendees to remove the PPI trial from EoE diagnostic criteria. Based on this meeting, a manuscript was written and circulated electronically. Outstanding issues, including

operationalizing the criteria and the approach to cases in which clinical presentations of GERD and EoE overlap (particularly an issue in pediatrics), were discussed on a series of teleconferences and e-mail discussions to establish uniform agreement before the final submission. This process included all co-authors, who each confirmed agreement with the consensus. Health benefits, adverse effects, and risks of findings were discussed as a part of these proceedings. The document was not externally reviewed before submission. A procedure for updating recommendations is provided.

**Clarity of Presentation.** The criteria provided are specific because they pertain to both children and adult patients and options are provided.

**Applicability.** Results from these proceedings provide advice and a practical approach for the clinical assessment and diagnosis of children and adults with suspected EoE. Facilitators and barriers relate primarily to distribution of criteria for practice. Monitoring and auditing of criteria will be addressed in future studies.

**Editorial Independence.** The views of the funders have not influenced the content of the guideline. Competing interests of AGREE team members have been recorded and addressed.

## Results

### Role of PPI Treatment of Esophageal Eosinophilia

To assess the role of PPI treatment in esophageal eosinophilia, we defined *suspected EoE* as symptoms of esophageal dysfunction and at least 15 eos/hpf (or  $\sim 60$  eos/mm<sup>2</sup>) on esophageal biopsy and defined *confirmed EoE* as symptoms of esophageal dysfunction and at least 15 eos/hpf (or  $\sim 60$  eos/mm<sup>2</sup>) on biopsy after evaluation for other causes of esophageal eosinophilia. We divided patients into either children or adolescents/adults based on the similarity of the clinical presentation within these age ranges (nonspecific vs dysphagia-predominant symptoms).<sup>31</sup> Full results are presented in online in the [Supplementary Material 1](#).

Although there were limited reports in children, there was evidence that PPIs could be used to treat esophageal eosinophilia in suspected EoE when response was measured by histologic improvement; clinical responses were less frequently studied, and it was difficult to draw conclusions about symptom benefit. Overall, histologic response ranged from 23% to 83%, and clinical responses were 23% to 82% ([Supplementary Figure 1A](#)). In a meta-analysis by Lucendo and colleagues, the pooled histologic response to PPI treatment in children with  $\geq 15$  eos/hpf was 54% (95% confidence interval, 38–70), although heterogeneity was high ( $I^2 = 66\%$ ).<sup>32</sup>

There was substantial evidence that PPIs can be used to treat esophageal eosinophilia in adolescents and adults with suspected EoE, when response was measured by histologic improvement. Histologic response rates ranged from 23% to 83% ([Supplementary Figure 1B](#)). The meta-analysis by Lucendo et al reported a pooled histologic response rate of 50% (95% CI, 40–59) for PPI use in adults, although there was substantial heterogeneity ( $I^2 = 70\%$ ).<sup>32</sup> In both adults and children, the wide variability in PPI responses rates is likely due to the heterogenous populations enrolled and

heterogeneous study designs; it was not possible to determine the role of overlapping GERD in most of these studies.

### Potential Mechanisms of PPI Response

The notion that resolution of symptomatic esophageal eosinophilia with PPI therapy established a diagnosis of GERD and excluded EoE was based on several assumptions: (1) gastric acid inhibition is the only important effect of PPIs; (2) acid reflux does not contribute to antigen-mediated esophageal eosinophilia; and (3) GERD is the only esophageal disease that responds to PPIs. Recent data suggest these assumptions may be flawed<sup>14</sup> and that several potential mechanisms may underlie PPI response (Supplementary Figures 2 and 3). These mechanisms include anti-inflammatory effects of PPIs unrelated to gastric acid suppression and gastric acid-inhibiting effects of PPIs including effects on barrier function (see Supplementary Material 1 for a full discussion). However, these mechanisms are primarily from in vitro data, multiple mechanisms may be involved, and the actual mechanism of action is not known in any given case.

### Principles for the Updated EoE Diagnostic Criteria

Several principles were considered as the updated diagnostic criteria were developed. First, because EoE was believed to be the same disease in children and adults<sup>33</sup> and any age cutoff would be arbitrary, the criteria were crafted to be applicable to all ages. Second, there was an emphasis on removing the PPI trial as part of the diagnostic criteria. Third, we emphasized the need to evaluate for conditions that might contribute to esophageal eosinophilia rather than require their exclusion. For patients with reflux symptoms, this would allow EoE and GERD to coexist. Fourth, there was a requirement that the criteria be operationalized in a clinically useful way. Finally, the criteria would need to have utility in both clinical practice and research trials and would need to be applicable to patients who had been diagnosed with EoE under prior guidelines. For research, this would also imply that not every EoE patient would be appropriate for inclusion in every clinical trial, and nonresponse to a PPI as an entry criterion may depend on the mechanism of the therapy under investigation and the label sought. The other important principle was that EoE remains, as conceptually defined in the 2011 guidelines, a chronic, immune/antigen-mediated esophageal disease characterized clinically by symptoms related to esophageal dysfunction and histologically by eosinophil-predominant inflammation, defined as  $\geq 15$  eos/hpf ( $\sim 60$  eos/mm<sup>2</sup>) in the vast majority of cases.

### Overview of the Updated EoE Diagnostic Criteria

**EoE Diagnostic Algorithm.** The updated diagnostic algorithm for EoE is shown in Figure 1, with diagnostic criteria listed in Table 2. EoE is suspected on a clinical basis with chronic symptoms of esophageal dysfunction, which could manifest in a variety of ways including but not limited to dysphagia, food impaction, food refusal, failure to




Figure 1. Updated EoE diagnostic algorithm.

progress with food introduction, heartburn, regurgitation, vomiting, chest pain, odynophagia, abdominal pain, and malnutrition. Atopic comorbidities such as asthma, atopic dermatitis, or immediate-type food allergies, as well as family history of EoE or dysphagia, should increase the clinical index of suspicion. Because these symptoms are nonspecific, patients should be treated as clinically indicated. For example, patients with dysphagia or food impaction may move to an EGD or other structural assessment as the first-line test and before any treatment, whereas patients with heartburn or vomiting may have other testing or medical treatment (eg, PPI for cases of suspected reflux), with need for endoscopy determined by clinical considerations. Because EoE presents with a wide range of symptoms, this algorithm cannot anticipate every clinical possibility and provides leeway for the age-appropriate evaluation deemed necessary.

When endoscopy is performed, the practitioner should evaluate for endoscopic signs of EoE (including esophageal rings, longitudinal furrows, exudates, edema, strictures, or narrow caliber esophagus, ideally quantified using the EoE Endoscopic Reference Score<sup>34</sup>) and for alternative esophageal disorders. In all cases where EoE is a clinical possibility (even when normal mucosa is visualized),<sup>35,36</sup> esophageal biopsy specimens should be obtained. As per prior guidelines, multiple biopsy specimens from 2 or more esophageal levels, targeting areas of apparent inflammation, are recommended to increase the diagnostic yield.<sup>3,4,11,37-39</sup> Gastric and duodenal biopsy specimens should be obtained as clinically indicated by symptoms, endoscopic findings in the stomach or duodenum, or high index of suspicion for a mucosal process. Although gastric and duodenal biopsies in the absence of symptoms or endoscopic abnormalities have a

Table 2. EoE Diagnostic Criteria

- Symptoms of esophageal dysfunction
  - Concomitant atopic conditions should increase suspicion for EoE.
  - Endoscopic findings of rings, furrows, exudates, edema, stricture, narrowing, and crepe paper mucosa should increase suspicion for EoE.
- $\geq 15$  eos/hpf ( $\sim 60$  eos/mm<sup>2</sup>) on esophageal biopsy
  - Eosinophilic infiltration should be isolated to the esophagus.
- Assessment of non-EoE disorders that cause or potentially contribute to esophageal eosinophilia

low yield in identifying other eosinophilic gastrointestinal disorders, they are routinely obtained in pediatric endoscopy and are recommended in prior pediatric EoE guidelines.<sup>9,12,40</sup>

At this stage in the algorithm, a patient would be considered to have clinically suspected EoE if there are symptoms of esophageal dysfunction and at least 15 eos/hpf (or  $\sim 60$  eos/mm<sup>2</sup>) on biopsy. There may be patients who enter the algorithm at this step, even if EoE was not a clinical consideration before the endoscopy and biopsy—for example, if the endoscopy was performed for a non-esophageal indication or for atypical reflux symptoms. The key point is that the presence of esophageal eosinophilia on histologic examination without further consideration of the clinical presentation is not diagnostic of EoE.<sup>4,11,41</sup>

Because of the data discussed, a PPI trial is not required for diagnosis of EoE in this algorithm. However, use of concomitant therapies must be considered when interpreting endoscopy and biopsy results.<sup>29,31</sup> A diagnosis of EoE cannot be definitively ruled out in patients who have an initial endoscopy on PPI therapy and have normal biopsy results, because their biopsy results in the absence of PPI therapy are not known. For patients who respond to PPI therapy, clinicians must decide whether ongoing long-term PPI therapy should be used or whether further evaluation without PPI therapy should be considered. Conversely, when patients receiving PPI treatment come to endoscopy, they may have endoscopic and biopsy findings consistent with EoE, but clinicians still need to follow through with the remainder of the diagnostic algorithm.

All patients with esophageal eosinophilia of  $\geq 15$  eos/hpf ( $\sim 60$  eos/mm<sup>2</sup>) should be evaluated for non-EoE disorders that cause or potentially contribute to esophageal eosinophilia. GERD continues to present a unique situation (see “Evaluating for the Contribution of GERD” section). Hyper-eosinophilic syndrome, non-EoE eosinophilic gastrointestinal disorders, achalasia, Crohn’s disease, infections, connective tissue disorders, and drug hypersensitivity reactions (Table 3) have been associated with esophageal

**Table 3.** Conditions Associated With Esophageal Eosinophilia

- Eosinophilic esophagitis
- Eosinophilic gastritis, gastroenteritis, or colitis with esophageal involvement
- GERD
- Achalasia and other disorders of esophageal dysmotility
- Hypereosinophilic syndrome
- Crohn’s disease with esophageal involvement
- Infections (fungal, viral)
- Connective tissue disorders
- Hypermobility syndromes
- Autoimmune disorders and vasculitides
- Dermatologic conditions with esophageal involvement (ie, pemphigus)
- Drug hypersensitivity reactions
- Pill esophagitis
- Graft vs host disease
- Mendelian disorders (Marfan syndrome type II, hyper-IgE syndrome, *PTEN* hamartoma tumor syndrome, Netherton syndrome, severe atopy metabolic wasting syndrome)

eosinophilia but are uncommon or present with clinical features that readily distinguish them from EoE.<sup>4,11</sup>

EoE is finally diagnosed after evaluation shows that there are no other causes substantially contributing to symptoms and esophageal eosinophilia. We define confirmed EoE as symptoms of esophageal dysfunction, at least 15 eos/hpf (or  $\sim 60$  eos/mm<sup>2</sup>) on biopsy, and evaluation showing no significant other causes of symptoms and/or esophageal eosinophilia. It is important that the definition of esophageal eosinophilia and EoE be uniform among adult and pediatric gastroenterologists, allergists, and pathologists, as well as among both clinicians and researchers.

### Complexities in EoE Diagnosis

**Phenotypic Variability.** A major complexity in EoE diagnosis is that there is substantial phenotypic variability in presentation based on age and duration of disease.<sup>31,42–45</sup> Diagnosis may be straightforward in a young man with food and environmental allergies; a long-standing history of dysphagia and food impaction; endoscopy showing rings, furrows, edema, and exudates; and esophageal eosinophilia. However, a child or adult presenting with heartburn,<sup>Q14</sup> nausea/vomiting, or epigastric pain and who has an endoscopy showing subtle edema and biopsy results showing esophageal eosinophilia ( $\geq 15$  eos/hpf) presents a distinctly different challenge. It is therefore key to understand the various presentations of esophageal eosinophilia and EoE and that the finding of increased eosinophils on biopsy cannot in isolation be equated with a definite diagnosis of EoE. In addition, we provide a set of illustrative cases (Supplementary Material 2) across the age and phenotypic spectrum to highlight how individual patients may fit into the presented diagnostic algorithm.

**Evaluating for the Contribution of GERD.** GERD is defined as a condition that develops when reflux of gastric contents causes troublesome symptoms and/or complications.<sup>46</sup> The lack of 1 single criterion standard for the diagnosis of GERD makes attempts at defining the accuracy of any individual test problematic. Composite definitions of GERD using a combination of reflux esophagitis, abnormal pH testing, symptom association probability metrics, and symptom response to PPI therapy have reported 42%–65% sensitivity and 70% specificity for validated symptom instruments for the diagnosis of GERD.<sup>47</sup> However, endoscopic features of GERD,<sup>48,49</sup> histologic features of basal zone hyperplasia, papillary elongation, inflammatory cell infiltrate and dilated intercellular spaces, and symptom response to PPI therapy<sup>47,50</sup> have limitations in both sensitivity and specificity. In some patients, because it may be difficult to ascertain the precise contribution of GERD to esophageal eosinophilia, clinical evaluation for GERD could be undertaken in concordance with published GERD guidelines before a definitive diagnosis of EoE.<sup>51,52</sup>

Available studies examining the distinction between GERD and EoE (Supplementary Material 3) are limited by study design, absence of comprehensive testing modalities, and the lack of a criterion standard to define either condition. Furthermore, the high background prevalence of GERD

**Table 4.** Future Research Directions Related to PPIs and Esophageal Eosinophilia

Research Category	Research Topic
Basic research	<ul style="list-style-type: none"> <li>• Interaction between GERD and EoE in animal models</li> <li>• Elucidation of mechanism of PPIs including anti-inflammatory effects in vitro and in vivo</li> <li>• Genetics of EoE as a function of PPI responsiveness</li> <li>• Transcriptome that distinguishes EoE as a function of PPI responsiveness</li> </ul>
Clinical/translational research	<ul style="list-style-type: none"> <li>• Comparison of PPIs with topical steroids and dietary elimination in treatment-naïve EoE patients</li> <li>• Comparative effectiveness of PPIs vs topical steroids or dietary elimination therapy</li> <li>• Assessment of efficacy of topical steroid and dietary elimination treatment in PPI responders</li> <li>• Determination of optimal short- and long-term PPI dosing, as well as safety of these chronic PPI dosing regimens <ul style="list-style-type: none"> <li>◦ Assess in the context of the <i>CPY2C19</i> genotype</li> <li>◦ Assess in nonwhite populations</li> </ul> </li> <li>• Determination of efficacy of PPIs on symptom response using validated instruments <ul style="list-style-type: none"> <li>◦ Assess whether symptom and histologic responses are concordant</li> <li>◦ Assess for differences in histologic responses in different levels of the esophagus</li> </ul> </li> <li>• Phenotypic and mechanistic distinctions between GERD-related, epithelial barrier-induced eosinophilia vs non-GERD atopic esophagitis with eosinophils</li> <li>• Assessment of the role of other non-PPI acid suppressive drugs (eg, vonoprazan or H<sub>2</sub> blockers)</li> <li>• Assessment of the role of PPI therapy in combination with either topical steroids or dietary elimination in partial responders to PPIs</li> <li>• Characterization of the natural history of esophageal eosinophilia related to <ul style="list-style-type: none"> <li>◦ Esophageal remodeling and fibrosis</li> <li>◦ Loss of PPI response</li> <li>◦ Recurrence of eosinophilia after stopping PPI</li> <li>◦ Risk of neoplasia and malignancy</li> </ul> </li> <li>• Characterization of the natural history of esophageal eosinophilia in the absence of symptoms of esophageal dysfunction</li> <li>• Implications of a prior PPI-REE diagnosis</li> <li>• Determination of predictors of PPI response, including molecular and genetic determinants</li> <li>• Determining role of environmental factors in EoE, particularly related to PPI responsiveness</li> <li>• Identifying EoE disease endotypes and their relationship to treatment responses such as PPI therapy</li> </ul>

(10%–20%) confounds efforts to differentiate GERD and EoE.<sup>46</sup> Adding PPI-REE to this discussion is a further complexity. Some patients with PPI-REE appear to have an increased GERD signature as evidenced by a higher degree of abnormal pH testing, symptoms of GERD, manometric features consistent with GERD, and fewer endoscopic features of EoE.<sup>6,8–10,53</sup> Assessing GERD features using tissue biomarkers or mucosal impedance may be useful in the future, because preliminary studies have been promising,<sup>17,54–58</sup> as have been some symptom scores.<sup>42,59–62</sup> Molecular studies show a substantial overlap in gene expression between EoE and PPI-REE and identify a molecular signature for the pathogenesis of EoE that is distinct from GERD.<sup>20,21,63–65</sup> At this time, though, there is no single test that can be used clinically to reliably distinguish EoE from GERD, and clinicians will need to take into account individual patient features and perform clinically indicated testing as needed. For example, a patient with erosive esophagitis and a peptic stricture might present with symptoms suggestive of EoE (dysphagia, heartburn) and have esophageal eosinophilia, but GERD would be the primary diagnosis. Additionally, when GERD and EoE overlap, patients will need management and follow-up of GERD and coexisting Barrett's esophagus, if present, as per published guidelines.<sup>51,66</sup>

**Initial Treatment and Follow-Up After EoE Is Confirmed.** It is beyond the scope of this article to provide

comprehensive recommendations for the treatment of EoE.<sup>29,31</sup> To date, no prospective, double-blind, randomized trial has compared the efficacies of steroids to PPI or diet to PPI. However, because of low cost, good safety profile, convenience, and a large body of literature describing PPI response in patients with esophageal eosinophilia and endoscopic findings suggestive of EoE, a PPI should be considered as a potential early or initial treatment, although swallowed steroids or dietary elimination may also be considered.<sup>27,29,32</sup> If diet or steroid therapy is used as a first-line therapy but is ineffective on follow-up endoscopy with biopsy, PPI therapy should be considered, because there is a good chance that this will be successful.<sup>67</sup> It is also necessary to realize that because GERD and EoE may coexist, some patients may need to be treated with both a PPI and different anti-inflammatory treatment (eg, dietary elimination or a topical steroids) to optimally treat both conditions, although there are few data on combination therapy. Finally, treatment decisions must be made with the understanding that most data on response rates for topical steroids, dietary elimination, and novel/emerging treatments in EoE are largely in the patient population that has failed to respond to PPI treatment previously.<sup>31,68,69</sup>

Because there are limited long-term treatment data available, patients with esophageal eosinophilia and EoE need to have close and structured follow-up with symptomatic, endoscopic, and histologic assessment. For those

who respond to a PPI and are maintained on these medications, regular clinical follow-up, including future endoscopies with biopsy, may be indicated because a proportion may lose response over time,<sup>70,71</sup> as can happen with other EoE therapies.<sup>72–76</sup> There are no data on outcomes in truly asymptomatic patients with esophageal eosinophilia. Because of concerns of progression from inflammation to fibrosis,<sup>43–45,77</sup> these patients also merit clinical follow-up.

**Approach to Clinical Trials and Regulatory Agencies.** As noted, one of the principles in updating EoE diagnostic criteria was to ensure that patients previously treated in clinical trials for EoE would still meet criteria for EoE diagnosis. Indeed, patients diagnosed with EoE as per prior guidelines (with failure to respond to a PPI trial) would still meet criteria as having EoE as per the updated guidelines, provided that other causes of and contributions to esophageal eosinophilia had been assessed. Going forward, however, a clinical trial design must specify and provide the rationale for the subtype of EoE population being included, be it PPI nonresponsive, PPI responsive, or PPI naïve. Similar considerations would be needed for other EoE treatments as well. These criteria will also allow new research and clinical trials to be conducted that will move the field forward. For example, patients who were previously diagnosed with PPI-REE might be reclassified as having EoE and could be enrolled into clinical trials.

### Future Research Directions

With updating the diagnostic algorithm for EoE and reviewing the literature related to the treatment effect of PPIs on esophageal eosinophilia, multiple gaps in knowledge and important research questions were identified (Table 4). This new algorithm acknowledges that in some cases there may be clinical ambiguity between EoE and GERD, or esophageal eosinophilia without symptoms, and in these situations ongoing close follow-up is mandatory. This document challenges researchers to continue to identify clinical phenotypes and understand the biology and clinical role of PPIs in patients with esophageal eosinophilia and EoE. In addition, understanding the mechanism of the dramatic effect of PPI therapy on type 2 allergic inflammation holds promise for treating EoE and other diseases characterized by similar processes. Together, this knowledge will help guide regulatory agencies, industry partners, and patient advocacy groups to understand the best subpopulations of EoE to study for drug and other therapeutic development, to continue to improve outcomes for all EoE patients.

### Conclusion

A tremendous amount of progress has been made in the understanding of EoE in the last 2 decades spanning clinical presentation, epidemiology, genetics, pathogenesis, treatment, and outcomes. With such a rapid evolution of knowledge, diagnostic criteria must also evolve. Although EoE and GERD were first believed to be distinct and separable by a PPI trial, there was increasing recognition that the relationship was far more complex, that they could co-exist,

and that each might influence the other. With the identification of patients who responded to PPI treatment, it was not initially known if PPI-REE was a subtype of EoE, an atypical manifestation of GERD, or a unique entity. Now, the evidence suggests that in many cases PPI-REE is indistinguishable from EoE and ta PPIs are better classified as a treatment for esophageal eosinophilia that may be due to EoE than as a diagnostic criterion. These updated international consensus criteria reflect this concept. As the field continues to develop and the research questions identified during this process are answered, the criteria presented here will evolve in the context of new data and advances.

### Supplementary Material

Note: To access the supplementary material accompanying this article, visit the online version of *Gastroenterology* at [www.gastrojournal.org](http://www.gastrojournal.org), and at <https://doi.org/10.1053/j.gastro.2018.07.009>.

### References

- Dellon ES, Aderoju A, Woosley JT, Sandler RS, Shaheen NJ. Variability in diagnostic criteria for eosinophilic esophagitis: a systematic review. *Am J Gastroenterol* 2007;102:2300–2313.
- Sperry SL, Shaheen NJ, Dellon ES. Toward uniformity in the diagnosis of eosinophilic esophagitis (EoE): the effect of guidelines on variability of diagnostic criteria for EoE. *Am J Gastroenterol* 2011;106:824–833.
- Furuta GT, Liacouras CA, Collins MH, et al. Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. *Gastroenterology* 2007;133:1342–1363.
- Liacouras CA, Furuta GT, Hirano I, et al. Eosinophilic esophagitis: updated consensus recommendations for children and adults. *J Allergy Clin Immunol* 2011;128:3–20.e6.
- Ngo P, Furuta GT, Antonioli DA, Fox VL. Eosinophils in the esophagus—peptic or allergic eosinophilic esophagitis? Case series of three patients with esophageal eosinophilia. *Am J Gastroenterol* 2006;101:1666–1670.
- Dranove JE, Horn DS, Davis MA, et al. Predictors of response to proton pump inhibitor therapy among children with significant esophageal eosinophilia. *J Pediatr* 2009;154:96–100.
- Sayej WN, Patel R, Baker RD, et al. Treatment with high-dose proton pump inhibitors helps distinguish eosinophilic esophagitis from noneosinophilic esophagitis. *J Pediatr Gastroenterol Nutr* 2009;49:393–399.
- Molina-Infante J, Ferrando-Lamana L, Ripoll C, et al. Esophageal eosinophilic infiltration responds to proton pump inhibition in most adults. *Clin Gastroenterol Hepatol* 2011;9:110–117.
- Dellon ES, Speck O, Woodward K, et al. Clinical and endoscopic characteristics do not reliably differentiate PPI-responsive esophageal eosinophilia and eosinophilic esophagitis in patients undergoing upper endoscopy: a prospective cohort study. *Am J Gastroenterol* 2013;108:1854–1860.

- 961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000  
1001  
1002  
1003  
1004  
1005  
1006  
1007  
1008  
1009  
1010  
1011  
1012  
1013  
1014  
1015  
1016  
1017  
1018  
1019  
1020
10. Francis DL, Foxx-Orenstein A, Arora AS, et al. Results of ambulatory pH monitoring do not reliably predict response to therapy in patients with eosinophilic oesophagitis. *Aliment Pharmacol Ther* 2012;35:300–307.
  11. **Dellon ES, Gonsalves N, Hirano I**, et al. ACG Clinical Guideline: evidence based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis. *Am J Gastroenterol* 2013; 108:679–692.
  12. Papadopoulou A, Koletzko S, Heuschkel R, et al. Management guidelines of eosinophilic esophagitis in childhood. *J Pediatr Gastroenterol Nutr* 2014;58: 107–118.
  13. Hirano I. Editorial: should patients with suspected eosinophilic esophagitis undergo a therapeutic trial of proton pump inhibition? *Am J Gastroenterol* 2013; 108:373–375.
  14. Spechler SJ, Genta RM, Souza RF. Thoughts on the complex relationship between gastroesophageal reflux disease and eosinophilic esophagitis. *Am J Gastroenterol* 2007;102:1301–1306.
  15. Moawad FJ, Schoepfer AM, Safroneeva E, et al. Eosinophilic oesophagitis and proton pump inhibitor-responsive oesophageal eosinophilia have similar clinical, endoscopic and histological findings. *Aliment Pharmacol Ther* 2014;39:603–608.
  16. Warners MJ, van Rhijn BD, Curvers WL, et al. PPI-responsive esophageal eosinophilia cannot be distinguished from eosinophilic esophagitis by endoscopic signs. *Eur J Gastroenterol Hepatol* 2015; 27:506–511.
  17. Dellon ES, Speck O, Woodward K, et al. Markers of eosinophilic inflammation for diagnosis of eosinophilic esophagitis and proton pump inhibitor-responsive esophageal eosinophilia: a prospective study. *Clin Gastroenterol Hepatol* 2014;12:2015–2022.
  18. Molina-Infante J, Rivas MD, Hernandez-Alonso M, et al. Proton pump inhibitor-responsive oesophageal eosinophilia correlates with downregulation of eotaxin-3 and Th2 cytokines overexpression. *Aliment Pharmacol Ther* 2014;40:955–965.
  19. Moawad FJ, Wells JM, Johnson RL, et al. Comparison of eotaxin-3 biomarker in patients with eosinophilic oesophagitis, proton pump inhibitor-responsive oesophageal eosinophilia and gastro-oesophageal reflux disease. *Aliment Pharmacol Ther* 2015;42:231–238.
  20. Wen T, Dellon ES, Moawad FJ, et al. Transcriptome analysis of proton pump inhibitor-responsive esophageal eosinophilia reveals proton pump inhibitor-reversible allergic inflammation. *J Allergy Clin Immunol* 2015; 135:187–197.
  21. Shoda T, Matsuda A, Nomura I, et al. Eosinophilic esophagitis versus proton pump inhibitor-responsive esophageal eosinophilia: transcriptome analysis. *J Allergy Clin Immunol* 2017;139:2010–2013.e4.
  22. Lucendo AJ, Arias A, Gonzalez-Cervera J, et al. Dual response to dietary/topical steroid and proton pump inhibitor therapy in adult patients with eosinophilic esophagitis. *J Allergy Clin Immunol* 2016; 137:931–934.e2.
  23. Sodikoff J, Hirano I. Proton pump inhibitor-responsive esophageal eosinophilia does not preclude food-responsive eosinophilic esophagitis. *J Allergy Clin Immunol* 2016;137:631–633.
  24. Cheng E, Zhang X, Huo X, et al. Omeprazole blocks eotaxin-3 expression by oesophageal squamous cells from patients with eosinophilic oesophagitis and GORD. *Gut* 2013;62:824–832.
  25. Zhang X, Cheng E, Huo X, et al. Omeprazole blocks STAT6 binding to the eotaxin-3 promoter in eosinophilic esophagitis cells. *PLoS One* 2012;7:e50037.
  26. van Rhijn BD, Weijnenborg PW, Verheij J, et al. Proton pump inhibitors partially restore mucosal integrity in patients with proton pump inhibitor-responsive esophageal eosinophilia but not eosinophilic esophagitis. *Clin Gastroenterol Hepatol* 2014;12:1815–1823.e2.
  27. Molina-Infante J, Bredenoord AJ, Cheng E, et al. Proton pump inhibitor-responsive oesophageal eosinophilia: an entity challenging current diagnostic criteria for eosinophilic oesophagitis. *Gut* 2016;65:524–531.
  28. Eluri S, Dellon ES. Proton pump inhibitor-responsive oesophageal eosinophilia and eosinophilic oesophagitis: more similarities than differences. *Curr Opin Gastroenterol* 2015;31:309–315.
  29. Lucendo AJ, Molina-Infante J, Arias A, et al. Guidelines on eosinophilic esophagitis: Evidence-based statements and recommendations for diagnosis and management in children and adults. *United European Gastroenterol J* 2017;5:335–358.
  30. Brouwers M, Kho ME, Brownman GP, et al. AGREE II: advancing guideline development, reporting and evaluation in healthcare. *Can Med Assoc J* 2010; 182:E839–E842.
  31. Dellon ES, Liacouras CA. Advances in clinical management of eosinophilic esophagitis. *Gastroenterology* 2014; 147:1238–1254.
  32. Lucendo AJ, Arias A, Molina-Infante J. Efficacy of proton pump inhibitor drugs for inducing clinical and histologic remission in patients with symptomatic esophageal eosinophilia: a systematic review and meta-analysis. *Clin Gastroenterol Hepatol* 2016;14:13–22.e1.
  33. Straumann A, Aceves SS, Blanchard C, et al. Pediatric and adult eosinophilic esophagitis: similarities and differences. *Allergy* 2012;67:477–490.
  34. Hirano I, Moy N, Heckman MG, et al. Endoscopic assessment of the oesophageal features of eosinophilic oesophagitis: validation of a novel classification and grading system. *Gut* 2013;62:489–495.
  35. Kim HP, Vance RB, Shaheen NJ, Dellon ES. The prevalence and diagnostic utility of endoscopic features of eosinophilic esophagitis: a meta-analysis. *Clin Gastroenterol Hepatol* 2012;10:988–996.e5.
  36. Dellon ES, Gebhart JH, Higgins LL, et al. The esophageal biopsy “pull” sign: a highly specific and treatment-responsive endoscopic finding in eosinophilic esophagitis (with video). *Gastrointest Endosc* 2016;83:92–100.
  37. Gonsalves N, Policarpio-Nicolas M, Zhang Q, et al. Histopathologic variability and endoscopic correlates in adults with eosinophilic esophagitis. *Gastrointest Endosc* 2006;64:313–319.

- 1081 38. Shah A, Kagalwalla AF, Gonsalves N, et al. Histopathologic variability in children with eosinophilic esophagitis. *Am J Gastroenterol* 2009;104:716–721. 1141
- 1082 39. Dellon ES, Speck O, Woodward K, et al. Distribution and variability of esophageal eosinophilia in patients undergoing upper endoscopy. *Mod Pathol* 2015; 28:383–390. 1142
- 1083 40. Kaur S, Rosen JM, Kriegermeier AA, et al. Utility of gastric and duodenal biopsies during follow-up endoscopy in children with eosinophilic esophagitis. *J Pediatr Gastroenterol Nutr* 2017;65:399–403. 1143
- 1084 41. Collins MH. Histopathologic features of eosinophilic esophagitis and eosinophilic gastrointestinal diseases. *Gastroenterol Clin North Am* 2014;43:257–268. 1144
- 1085 42. Dellon ES, Gibbs WB, Fritchie KJ, et al. Clinical, endoscopic, and histologic findings distinguish eosinophilic esophagitis from gastroesophageal reflux disease. *Clin Gastroenterol Hepatol* 2009;7:1305–1313. 1145
- 1086 43. Schoepfer AM, Safroneeva E, Bussmann C, et al. Delay in diagnosis of eosinophilic esophagitis increases risk for stricture formation in a time-dependent manner. *Gastroenterology* 2013;145:1230–1236.e2. 1146
- 1087 44. Dellon ES, Kim HP, Sperry SL, et al. A phenotypic analysis shows that eosinophilic esophagitis is a progressive fibrostenotic disease. *Gastrointest Endosc* 2014;79: 577–585.e4. 1147
- 1088 45. Lipka S, Kumar A, Richter JE. Impact of diagnostic delay and other risk factors on eosinophilic esophagitis phenotype and esophageal diameter. *J Clin Gastroenterol* 2016;50:134–140. 1148
- 1097 46. Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. *Am J Gastroenterol* 2006;101:1900–1920. 1149
- 1098 47. Dent J, Vakil N, Jones R, et al. Accuracy of the diagnosis of GORD by questionnaire, physicians and a trial of proton pump inhibitor treatment: the Diamond Study. *Gut* 2010;59:714–721. 1150
- 1099 48. Ayazi S, Lipham JC, Portale G, et al. Bravo catheter-free pH monitoring: normal values, concordance, optimal diagnostic thresholds, and accuracy. *Clin Gastroenterol Hepatol* 2009;7:60–67. 1151
- 1100 49. Jamieson JR, Stein HJ, DeMeester TR, et al. Ambulatory 24-h esophageal pH monitoring: normal values, optimal thresholds, specificity, sensitivity, and reproducibility. *Am J Gastroenterol* 1992;87:1102–1111. 1152
- 1101 50. Numans ME, Lau J, de Wit NJ, Bonis PA. Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics. *Ann Intern Med* 2004; 140:518–527. 1153
- 1102 51. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. *Am J Gastroenterol* 2013;108:308–328. 1154
- 1103 52. Molina-Infante J, Lucendo AJ. Proton pump inhibitor therapy for eosinophilic esophagitis: a paradigm shift. *Am J Gastroenterol* 2017;112:1770–1773. 1155
- 1104 53. Savarino EV, Tolone S, Bartolo O, et al. The GerdQ questionnaire and high resolution manometry support the hypothesis that proton pump inhibitor-responsive oesophageal eosinophilia is a GERD-related phenomenon. *Aliment Pharmacol Ther* 2016;44:522–530. 1156
- 1105 54. Kirsch R, Bokhary R, Marcon MA, Cutz E. Activated mucosal mast cells differentiate eosinophilic (allergic) esophagitis from gastroesophageal reflux disease. *J Pediatr Gastroenterol Nutr* 2007;44:20–26. 1157
- 1106 55. Dellon ES, Chen X, Miller CR, et al. Tryptase staining of mast cells may differentiate eosinophilic esophagitis from gastroesophageal reflux disease. *Am J Gastroenterol* 2011;106:264–271. 1158
- 1107 56. Dellon ES, Chen X, Miller CR, et al. Diagnostic utility of major basic protein, eotaxin-3, and leukotriene enzyme staining in eosinophilic esophagitis. *Am J Gastroenterol* 2012;107:1503–1511. 1159
- 1108 57. Katzka DA, Ravi K, Geno DM, et al. Endoscopic mucosal impedance measurements correlate with eosinophilia and dilation of intercellular spaces in patients with eosinophilic esophagitis. *Clin Gastroenterol Hepatol* 2015;13:1242–1248. 1160
- 1109 58. Ates F, Yuksel ES, Higginbotham T, et al. Mucosal impedance discriminates GERD from non-GERD conditions. *Gastroenterology* 2015;148:334–343. 1161
- 1110 59. Aceves SS, Newbury RO, Dohil MA, et al. A symptom scoring tool for identifying pediatric patients with eosinophilic esophagitis and correlating symptoms with inflammation. *Ann Allergy Asthma Immunol* 2009; 103:401–406. 1162
- 1111 60. Mulder DJ, Hurlbut DJ, Noble AJ, Justinich CJ. Clinical features distinguish eosinophilic and reflux-induced esophagitis. *J Pediatr Gastroenterol Nutr* 2013;56: 263–270. 1163
- 1112 61. Dellon ES, Rusin S, Gebhart JH, et al. A clinical prediction tool identifies cases of eosinophilic esophagitis without endoscopic biopsy: a prospective study. *Am J Gastroenterol* 2015;110:1347–1354. 1164
- 1113 62. von Arnim U, Rohl FW, Miehke S, et al. Clinical symptom tool that raises the index of suspicion for eosinophilic esophagitis in adults and drives earlier biopsy for definitive diagnosis. *Aliment Pharmacol Ther* 2017; 45:417–426. 1165
- 1114 63. Wen T, Stucke EM, Grotjan TM, et al. Molecular diagnosis of eosinophilic esophagitis by gene expression profiling. *Gastroenterology* 2013;145:1289–1299. 1166
- 1115 64. Dellon ES, Veerappan R, Selitsky SR, et al. A Gene expression panel is accurate for diagnosis and monitoring treatment of eosinophilic esophagitis in adults. *Clin Transl Gastroenterol* 2017;8:e74. 1167
- 1116 65. Dellon ES, Yellore V, Andreatta M, Stover J. A single biopsy is valid for genetic diagnosis of eosinophilic esophagitis regardless of tissue preservation or location in the esophagus. *J Gastrointest Liver Dis* 2015; 24:151–157. 1168
- 1117 66. Shaheen NJ, Falk GW, Iyer PG, Gerson LB. ACG Clinical Guideline: diagnosis and management of Barrett's esophagus. *Am J Gastroenterol* 2016;111:30–50. 1169
- 1118 67. Muir AB, Wang ML, Metz D, et al. Proton pump inhibitor-responsive oesophageal eosinophilia: too early to change clinical practice. *Gut* 2017;66:979–980. 1170
- 1119 68. Cotton CC, Eluri S, Wolf WA, Dellon ES. Six-food elimination diet and topical steroids are effective for 1171
- 1172
- 1173
- 1174
- 1175
- 1176
- 1177
- 1178
- 1179
- 1180
- 1181
- 1182
- 1183
- 1184
- 1185
- 1186
- 1187
- 1188
- 1189
- 1190
- 1191
- 1192
- 1193
- 1194
- 1195
- 1196
- 1197
- 1198
- 1199
- 1200

- eosinophilic esophagitis: a meta-regression. *Dig Dis Sci* 2017;62:2408–2420.
69. Furuta GT, Katzka DA. Eosinophilic esophagitis. *N Engl J Med* 2015;373:1640–1648.
70. Dohil R, Newbury RO, Aceves S. Transient PPI responsive esophageal eosinophilia may be a clinical sub-phenotype of pediatric eosinophilic esophagitis. *Dig Dis Sci* 2012;57:1413–1419.
71. Molina-Infante J, Rodriguez-Sanchez J, Martinek J, et al. Long-term loss of response in proton pump inhibitor-responsive esophageal eosinophilia is uncommon and influenced by CYP2C19 genotype and rhinoconjunctivitis. *Am J Gastroenterol* 2015;110:1567–1575.
72. Dellon ES, Katzka DA, Collins MH, et al. Safety and efficacy of oral budesonide suspension for maintenance therapy in eosinophilic esophagitis: results from a prospective open-label study of adolescents and adults. *Gastroenterology* 2016;150(Suppl 1):S188.
73. Eluri S, Runge TM, Hansen J, et al. Diminishing effectiveness of long-term maintenance topical steroid therapy in PPI nonresponsive eosinophilic esophagitis. *Clin Transl Gastroenterol* 2017;8:e97.
74. Rajan J, Newbury RO, Anilkumar A, et al. Long-term assessment of esophageal remodeling in patients with pediatric eosinophilic esophagitis treated with topical corticosteroids. *J Allergy Clin Immunol* 2016;137:147–156.e8.
75. Philpott H, Nandurkar S, Royce SG, et al. A prospective open clinical trial of a proton pump inhibitor, elimination diet and/or budesonide for eosinophilic esophagitis. *Aliment Pharmacol Ther* 2016;43:985–993.
76. Reed CC, Fan C, Koutlas NT, et al. Food elimination diets are effective for long-term treatment of adults with eosinophilic esophagitis. *Aliment Pharmacol Ther* 2017;46:836–844.
77. Dellon ES, Hirano I. Epidemiology and natural history of eosinophilic esophagitis. *Gastroenterology* 2018;154:319–322.e3.

Author names in bold designate shared co-first authorship.

Received March 6, 2018. Accepted July 3, 2018.

#### Reprint requests

Address requests for reprints to: Evan S. Dellon, MD, MPH, CB #7080, Room 4140 Bioinformatics Building, 130 Mason Farm Road, Chapel Hill, North Carolina 27599-7080. e-mail: [edellon@med.unc.edu](mailto:edellon@med.unc.edu); fax: (919) 843-2508.

#### Acknowledgments

The authors gratefully acknowledge the input and collaboration from the patient advocacy groups, including American Partnership for Eosinophilic Disorders (APFED), Campaign Urging Research for Eosinophilic Disease (CURED), and Eosinophilic Family Coalition (EFC). We would also like to acknowledge Linda Perez for her administrative assistance with both the AGREE conference and with the manuscript preparation and Angelika Zalewski for her assistance with coordinating the AGREE conference.

Evan S. Dellon, Chris A. Liacouras, Javier Molina-Infante, Glenn T. Furuta, Jonathan M. Spergel, Noam Zevit, Stuart J. Spechler, Stephen E. Attwood, Alex Straumann, Ikuo Hirano, and Albert J. Bredenoord are AGREE Team conference leaders.

Author contributions: Project conception/design: Evan S. Dellon, Glenn T. Furuta, Ikuo Hirano, and Javen M. Sheikh. Drafting of the article: Evan S. Dellon, Chris A. Liacouras, Javier Molina-Infante, Glenn T. Furuta, Jonathan M. Spergel, Noam Zevit, Stuart J. Spechler, Stephen E. Attwood, Alex Straumann, Ikuo Horano, and Albert J. Bredenoord. Data review/interpretation, critical revision, and approval of final draft: all authors.

#### Conflicts of interest

These authors disclose the following: Evan S. Dellon has served as a consultant for Adare, Allakos, Alivio, Banner, Celgene/Receptos, Enumeral, GSK, Regeneron, and Shire; received research funding from Adare, Celgene/Receptos, Miraca, Meritage, Nutricia, Regeneron, and Shire; and received an educational grant from Banner and Holoclara. Chris A. Liacouras has served as a consultant for Shire, Adare, Abbott Nutrition, Receptos, and TEVA. Molina-Infante and received research funding from and served as a consultant for Dr. Falk Pharma. Glenn T. Furuta is founder of EnteroTrack, has served as a consultant for Shire, and received royalties from UpToDate. Jonathan M. Spergel has served as a consultant for Regeneron, DBV Technology, Kaleo, Grant-DBV Technology, Aimmune Therapeutics, Food Allergy Research Education; received royalties from UpToDate and Straumann; has consultant agreements with Actelion, AstraZeneca, Calypso, Celgene-Receptos, Falk, GSK, Sanofi-Regeneron, Tillotts, and Zealand; and received research funding from Falk. Stuart J. Spechler has served as a consultant for Ironwood Pharmaceuticals and Takeda Pharmaceuticals and received royalties from UpToDate. Stephen E. Attwood has served as a consultant for Dr Falk Pharma. Alex Straumann has served as a consultant for Actelion, Calypso, Falk, GSK, Novartis, Nutricia, Pfizer, Receptos-Celgene, Regeneron-Sanofi, Roche-Genentech, and Tillotts. Seema A. Aceves has served as a consultant for Regeneron; received research funding from Ferring Research Institute and receives patent royalties as co-inventor of oral viscous budesonide, Shire Pharma licensed. Jeffrey A. Alexander has financial interest in Meritage Pharmacia. Dan Atkins has served as a consultant for DBV Technology. Carine Blanchard is employed by Nestec Ltd. Mira Chehade has served as a consultant for Actelion, Shire, and Allakos and received research funding from Nutricia, Shire, and Regeneron. Etaire Cheng has served as a consultant for Abbott Nutrition. Margaret H. Collins has served as a consultant for Shire, Regeneron, Receptos, and Adare and received research funding from Shire, Regeneron, and Receptos. Carla M. Davis is an advisor for Moonlight Therapeutics, Inc; received research support from Nutricia North America, DBV Technologies, and Aimmune Therapeutics; has served as a consultant for Aimmune Therapeutics; and received an educational grant from Mylan. Jorge A. Dias has served as a consultant for Danone, AbbVie, and Shire. Carlo Di Lorenzo has served as a consultant for Shire, QOL, Sucampo, and Bayer; Ranjan Dohil, The University of California, San Diego has a financial interest in Shire Pharmaceuticals, the company to which oral viscous budesonide is licensed. Ranjan Dohil and the University of California, San Diego may financially benefit from this interest if the company is successful in developing and marketing its own product. The terms of the arrangement have been reviewed by the University of California, San Diego in accordance with its conflict of interest policies. Gary W. Falk received research funding from Adare, Shire, Regeneron, and Celgene/Receptos. Christina T. Ferreira has served as a consultant and/or speaker for Danone, Farnocquímica, and Alexion; Adam Fox has served as a consultant for Abbott Nutrition, Danone, Mead Johnson, and Nestle; received research funding from Danone Gonsalves; received royalties from UpToDate; and served on the advisory board of Allakos. Sandeep K. Gupta has served as a consultant for Abbott, Allakos, QOL, Receptos, and Shire and received research support from Shire. David A. Katzka received research funding from Shire. Yoshiakazu Kinoshita has served as a consultant for Eisai, EA Pharma, AstraZeneca, Daiichi-Sankyo, Takea, and Otsuka and received research funding from Eisai, AstraZeneca, Daiichi-Sankyo, Takeda, and Otsuka; David C. Metz has served as a consultant for Novartis and Takeda and received research support from AAA, Ipsen, Lexicon, and Wren Laboratories. Stephan Miehlke has received speaker's honoraria from Dr. Falk Pharma. Amanda B. Muir received research funding from Holoclara. Vincent A. Mukkada has served as a consultant for Shire. Simon Murch received lecture fees from Nutricia. Samuel Nurko has served as a consultant for Sucampo Pharmaceutica. Rok Oreil has served as a consultant and/or speaker for Nutricia, BioGaia, Medis, AbbVie, Lek, and Dr Falk. Alexandra Papadopoulou received speaker's honoraria and/or research grants from Nestle, Nutricia, and Vianex. Hamish Philpott received educational support from Aspen Australia. Rachel Rosen has served as a consultant for Jansen Pharmaceuticals. Marc E. Rothenberg has served as a consultant for Pulm One, Spoon Guru, Celgene, Shire, Astra Zeneca, GlaxoSmithKline, Allakos, Adare, Regeneron, and Novartis; has an equity interest in the first 3 listed and Immune Pharmaceuticals; received royalties from reslizumab (Teva Pharmaceuticals); and is an inventor of patents owned by Cincinnati Children's. Alain Schoepfer has served as a consultant for Adare, Falk, Receptos, and Regeneron. Neil Shah has provided unrestricted lectures and consultancy work for Nutricia, Nestle Health Sciences, and Mead Johnson. Mary J. Souza has served as a consultant for Ironwood Pharmaceuticals. Nicholas J. Talley received grant/research support from Rome Foundation, Abbott Pharmaceuticals, Datapharm, Pfizer, Salix, Prometheus Laboratories, and Janssen and has served on consultant/advisory boards for Adelphi Values GI Therapies Allergens PLC, Napo Pharmaceutical, Outpost Medicine, Samsung Bioepis, Yuhan, Synergy, and Theravance. Michael F. Vaezi received research support from Diversatek Healthcare, Vanderbilt University, and Diversatek Healthcare Inc. (Denver, CO) and jointly holds a patent on the mucosal impedance technology discussed. Yvan Vandenplas participated as a clinical investigator, and/or advisory board member, and/or consultant, and/or

1261  
1262  
1263  
1264  
1265  
1266  
1267  
1268  
1277  
1278  
1279  
1280  
1281  
1282  
1283  
1284  
1285  
1286  
1287  
1288  
1289  
1290  
1291  
1292  
1293  
1294  
1295  
1296  
1297  
1298  
1299  
1300  
1301  
1302  
1303  
1304  
1305  
1306  
1307  
1308  
1309  
1310  
1311  
1312  
1313  
1314  
1315  
1316  
1317  
1318  
1319  
1320

1321 speaker for Abbott Nutrition, Aspen, Biocodex, Danone, Nestle Health Science,  
 1322 Nestle Nutrition Institute, Nutricia, Mead Johnson Nutrition, Rontis, United  
 1323 Pharmaceuticals, and Wyeth. Mario C. Vieira has served as a consultant  
 1324 and/or speaker for Danone, Nestlé Nutrition Institute, and Aché Laboratories.  
 1325 Marjorie M. Walker received research funding from Prometheus Laboratories.  
 1326 Barry K. Wershil has served on the speaker bureau for Mead Johnson  
 1327 Nutrition and Abbott Nutrition. Ikuo Hirano has served as a consultant for  
 1328 Adare, Allakos, Celgene/Receptos, Regeneron, and Shire and received  
 research funding from Adare, Celgene/Receptos, Meritage, Regeneron, and  
 Shire. Albert J. Bredenoord has served as a consultant for AstraZeneca,  
 Given, MMS, Sandhill, Falk, Bayer, Nutricia, Allergan, Astellas, and Shire and

received research funding from Given, MMS, Falk, Bayer, Nutricia, and Shire.  
 The remaining authors disclose no conflicts.

#### Funding

This work was supported by The International Gastrointestinal Eosinophilic  
 Diseases Researchers (TIGERS); The David and Denise Bunning Family;  
 U54AI117804 (CEGIR), which is part of the Rare Disease Clinical Research  
 Network (RDCRN), an initiative of the Office of Rare Disease Research  
 (ORDR) and NCATS and is funded through collaboration between NIAID,  
 NIDDK, NCATS, and patient advocacy groups including APFED, CURED,  
 and EFC; and NIH K24DK100303 (to Glenn T. Furuta).

Q8 1381  
 1382  
 1383  
 1384  
 1385  
 1386  
 1387  
 Q9 Q24 1388  
 1389  
 1390  
 1391  
 1392  
 1393  
 1394  
 1395  
 1396  
 1397  
 1398  
 1399  
 1400  
 1401  
 1402  
 1403  
 1404  
 1405  
 1406  
 1407  
 1408  
 1409  
 1410  
 1411  
 1412  
 1413  
 1414  
 1415  
 1416  
 1417  
 1418  
 1419  
 1420  
 1421  
 1422  
 1423  
 1424  
 1425  
 1426  
 1427  
 1428  
 1429  
 1430  
 1431  
 1432  
 1433  
 1434  
 1435  
 1436  
 1437  
 1438  
 1439  
 1440

## Supplementary Material 1


### Role of PPI Treatment of Esophageal Eosinophilia

To assess the role of PPI treatment in esophageal eosinophilia, we defined *suspected EoE* as symptoms of esophageal dysfunction and at least 15 eos/hpf (or  $\sim 60$  eos/mm<sup>2</sup>) on esophageal biopsy and *confirmed EoE* as symptoms of esophageal dysfunction, at least 15 eos/hpf (or  $\sim 60$  eos/mm<sup>2</sup>) on biopsy, after evaluation for other causes of esophageal eosinophilia. We divided patients into either children or adolescents/adults, based on the similarity of the clinical presentation within these age ranges (nonspecific vs dysphagia-predominant symptoms).<sup>1</sup>

**PPI Treatment in Children.** Most studies on severe ( $\geq 15$  eos/hpf) pediatric esophageal eosinophilia had been conducted since 2006 and were largely retrospective or were case studies with varying PPI doses and duration of therapy,<sup>2-8</sup> although 2 more recent studies were prospective.<sup>7,8</sup> Although there were limited reports in children, there was evidence that PPIs could be used to treat esophageal eosinophilia when response was measured by histologic improvement; clinical responses were less frequently studied, and it was difficult to draw conclusions about symptom benefit with the current data. Overall, excluding the individual case series, histologic response

rates ranged from 23% to 83%, and clinical response rates were 23%–82% (Supplementary Figure 1A).

Ngo et al reported a series of 3 patients, of whom 2 were younger than 18 years.<sup>3</sup> Both patients had esophageal eosinophilia that responded to a PPI (PPI dose between 1 and 2 mg/kg/d). In a retrospective study in 2009 by Sayej et al, 14 of 36 patients who had esophageal eosinophilia showed a significant response to PPI therapy (PPI dose varied).<sup>4</sup> That same year, Dranove et al conducted a retrospective study of 43 patients with esophageal eosinophilia who were treated with an average of 1 mg/kg/d of PPI therapy for an unknown duration.<sup>2</sup> Of these, histology improved in 17 from  $>15$  eos/hpf to  $<5$  eos/hpf, and only 41% had an abnormal pH probe result. In a 2013 prospective study, Rea et al found that 15 of 25 patients with severe esophageal eosinophilia responded to PPI (exact doses unknown).<sup>7</sup> Interestingly, 4 patients who underwent Nissen fundoplication continued to have normal esophageal histology results and no longer needed PPI therapy, indicating that some of the response could be due to reflux. Similarly, Gutierrez-Junquera et al. reported a prospective study of 51 patients who received up to 1 mg/kg twice daily of PPI therapy for 8 weeks<sup>8</sup>; 47% showed complete histologic resolution, and 22% had a partial histologic response. Fourteen patients were followed up for a year maintained on 1 mg/kg once daily of PPI therapy; 9 maintained a complete response, and 2 maintained a partial response.



**Supplementary Figure 1.** Summary of histologic and clinical response rates for PPI treatment of esophageal eosinophilia in studies with  $>5$  subjects reported. (A) Studies in children. (B) Studies in adolescents/adults.

In a meta-analysis by Lucendo and colleagues assessing PPIs for treatment of symptomatic esophageal eosinophilia, the pooled histologic response to PPI treatment in children with  $\geq 15$  eos/hpf was 54% (95% confidence interval [CI], 38–70), although heterogeneity was high ( $I^2 = 66\%$ ).<sup>9</sup> The clinical response was even higher (65%; 95% CI, 43–84), but so was the heterogeneity ( $I^2 = 84\%$ ). Responses were similar regardless of PPI dosing. These results must be interpreted in the context of limitations in the literature. For example, the etiology of esophageal eosinophilia has not been well studied; in particular, the relation between allergen/immune-mediated vs acid/peptic-mediated mechanisms of eosinophilia remain unclear. Some patients with esophageal eosinophilia who responded to PPI therapy also improved after having a Nissen fundoplication,<sup>7</sup> whereas other patients who responded may or may not have had abnormal pH probe results.<sup>2</sup> The durability of the response to PPI therapy in children has also been questioned in some reports.<sup>5,6</sup>

Because the definition of EoE in children has included nonresponse to PPI therapy, there are no data that compare PPIs as the primary treatment of children with dietary elimination or topical steroids. Most of the data in children/adolescents were based on using diet or topical steroids only after PPI therapy had already failed.<sup>1</sup> The available evidence shows that the optimal dose of PPI therapy to induce remission of severe esophageal eosinophilia is up to 1 mg/kg twice a day (although some studies have shown a response with less than this dose), with a maximum of 30 mg twice a day of lansoprazole and 40 mg twice a day of omeprazole, for approximately 8 weeks.

**PPI Treatment in Adolescent and Adults.** There was substantial evidence that PPIs can be used to treat esophageal eosinophilia in adolescents and adults with suspected EoE when the response was measured by histologic improvement. The studies that provide this evidence include case reports/series and retrospective studies,<sup>3,10–20</sup> prospective investigations,<sup>21–31</sup> and randomized clinical trials.<sup>32,33</sup> The reported rates for histologic response to PPI treatment in these studies ranged from 23% to 83% (Supplementary Figure 1B). The meta-analysis by Lucendo et al reported a pooled histologic response rate of 50% (95% CI, 40–59) for PPI use in adults, although there was substantial heterogeneity ( $I^2 = 70\%$ ).<sup>9</sup> Overall, the interpretation of the data is limited by a number of small studies with retrospective designs, lack of what would be termed an *adequate* PPI trial with twice daily dosing for at least 8 weeks,<sup>34,35</sup> lack of a consistent definition of *histologic response*, few data on PPI response in non-White predominant populations, and lack of randomized clinical trials incorporating all of these features.

When examining the set of prospective studies alone,<sup>21–33</sup> the range of histologic responses to PPI was 23%–74%, and in the meta-analysis the pooled rate was 53% (95% CI, 44–61;  $I^2 = 53\%$ ).<sup>9</sup> Complicating the interpretation is the fact that 4 different histologic thresholds were used to define response ( $<5$  eos/hpf,<sup>26,31</sup>  $<7$  eos/hpf,<sup>33</sup>  $\leq 10$  eos/hpf,<sup>21</sup> and  $<15$  eos/hpf<sup>23–25,27,29,30,32</sup>), and 2 studies did not specify a


histologic response threshold.<sup>22,28</sup> When examining the prospective studies that used high-dose or twice daily PPI treatment,<sup>21–24,26–31</sup> we found that the range of histologic responses was also 23%–74% and the pooled rate was 56% (95% CI, 46–66;  $I^2 = 60\%$ ).<sup>9</sup>

There were 2 clinical trials that randomized patients with suspected EoE to receive either a PPI or a topical steroid.<sup>32,33</sup> In the study by Peterson et al,<sup>32</sup> 15 subjects were randomized to receive esomeprazole 40 mg daily, and 15 were randomized to swallowed fluticasone 440  $\mu\text{g}$  twice daily, both for an 8-week course; 12 and 13 subjects in each group, respectively, completed treatment. Six patients (50%) in the esomeprazole arm and 4 patients (31%) in the fluticasone arm achieved the  $\leq 15$  eos/hpf histologic endpoint ( $P = .28$ ). In the study by Moawad et al, the same treatment arms and dosages were used, with 21 subjects in each arm.<sup>33</sup> A total of 7 patients (33%) in the esomeprazole arm and 4 patients (19%) in the fluticasone arm achieved the  $\leq 15$  eos/hpf histologic endpoint ( $P = .48$ ). These rates of PPI response are lower than the pooled rates described for the high-dose PPI treatments and are also lower than the pooled rates reported for once daily PPI use (50%; 95% CI, 29–54).<sup>9</sup>

Although the evidence would suggest that PPIs have a beneficial impact on symptoms in patients with suspected EoE, there are a number of limitations to consider. Symptom or clinical response rates ranged from 25% to 96% in the referenced studies, but most studies did not report or quantify a specific response threshold. In addition, part of the symptomatic improvement could be due to typical reflux symptoms that respond to acid inhibition, or even acid hypersensitivity, in EoE despite lack of documented GERD.<sup>36</sup> In a meta-analysis, the pooled clinical response rate in adults is higher than the histologic response rate (56%; 95% CI, 41–70), but with a high degree of heterogeneity ( $I^2 = 78\%$ ).<sup>9</sup> It is difficult to interpret these data. No studies measured symptoms or quality of life using a validated EoE metric, and most studies reported a general or overall symptom improvement, which is difficult to compare between studies. Although some studies showed histologic/symptomatic concordance,<sup>37,38</sup> others showed absence of symptoms in some patients despite recurrent eosinophilia when the PPI dose was lowered.<sup>30,39</sup> This lack of rigor in symptom measurement, coupled with the heterogeneity already discussed, makes understanding the impact of PPIs on symptoms of suspected EoE a priority for future research (see below).

Similar to in children, there is currently little published evidence examining the use of PPIs as a primary (or first-line) treatment in adolescents and adults with confirmed EoE. Nevertheless, there is substantial clinical experience with using a PPI before treating with either a topical steroid or dietary elimination. In fact, most randomized controlled trials of topical steroid treatment in EoE required nonresponse to a PPI, as did many of the large studies of dietary elimination in EoE.<sup>1</sup> Therefore, current response rates for topical steroids and dietary elimination must be assessed in the context that the patients under study were PPI nonresponders.





**Supplementary Figure 3.** Proposed Mechanism of PPI inhibition of Th2-cytokine-stimulated eotaxin-3 expression. Th2 cytokine, IL-13 (or IL-4), can stimulate eotaxin-3 expression via signal transducer and activator of transcription 6 (STAT6) signaling in esophageal epithelial cells. However, in the presence of a PPI such as omeprazole, binding of both STAT6 and RNA polymerase II (RNA Pol II) to the eotaxin-3 promoter is decreased, and transcription of eotaxin-3 mRNA is reduced.

*Gastric Acid-Inhibiting Effects of PPIs That Might Reduce Esophageal Eosinophilia.* By impairing esophageal mucosal barrier integrity, GERD can render the esophageal mucosa permeable to swallowed antigens, which conceivably could contribute to the development of EoE. A number of studies have shown that esophageal acid exposure impairs esophageal mucosal integrity.<sup>64-67</sup> Acid reflux-induced impairment of mucosal integrity is manifested histologically by dilated intercellular spaces (DIS) and functionally by increased permeability to molecules as large as some peptide antigens.<sup>64-66</sup> DIS is a characteristic histologic feature of both erosive and nonerosive GERD, and in patients with GERD, PPI treatment can reverse DIS.<sup>68</sup> EoE genetic susceptibility is associated with genes that impair esophageal barrier function such as *FLG*, *DSG1*, *CAPN14*, and *SPINK5*, and genetic variability in these gene products may predispose the esophagus to increased acid sensitivity and/or responses.<sup>69</sup>

DIS and impaired mucosal integrity are also characteristic features of EoE.<sup>70</sup> The expression of intercellular adhesion molecules that maintain mucosal integrity is impaired in EoE patients,<sup>71</sup> who can exhibit increased esophageal mucosal permeability to molecules the size of some food allergens.<sup>72</sup> PPIs restore mucosal integrity and correct the abnormal mucosal permeability.<sup>21</sup> It is thus likely that in some EoE patients, acid reflux contributes to EoE by impairing mucosal integrity and enabling antigens to penetrate the esophageal mucosa and that PPIs work by reducing the secretion of the gastric acid that renders the esophageal mucosa permeable to food antigens. In support of acid reduction as the mechanism underlying

the beneficial effect of PPIs in esophageal eosinophilia, vonoprazan (a potassium-competitive acid blocker that is a potent inhibitor of gastric acid secretion) reduced esophageal eosinophilia substantially in 3 of 4 EoE patients.<sup>73</sup> In support of the concept that increased mucosal permeability contributes to EoE, some non-GERD disorders that impair esophageal mucosal barrier function (eg, infectious esophagitis, caustic ingestion) have been associated with later development of EoE or esophageal eosinophilia.<sup>74-77</sup>

It is not clear which of the potential PPI effects discussed are responsible for resolution of esophageal eosinophilia. However, the data suggest at least 3 possible clinical scenarios. First, patients might have GERD as the sole cause of esophageal eosinophilia, and their GERD responds to PPI acid-inhibitory effects, PPI anti-inflammatory effects, or both. Second, patients might respond to anti-inflammatory effects of PPIs independent of the effect of PPIs on acid. A third possibility is that GERD is exacerbating or causing an antigen-driven esophageal eosinophilia. Such patients might respond to both the anti-secretory and anti-inflammatory effects of PPIs.

**PPI Safety Considerations.** There are no unique safety considerations for PPI use in children, adolescents, or adults with EoE for standard (US Food and Drug Administration-approved, daily) dosing regimens beyond those that are already recognized for non-EoE indications.<sup>78</sup> A full discussion of potential adverse effects, including the controversy surrounding recent reports, is beyond the scope of this article and has been fully discussed elsewhere.<sup>78-81</sup>

## Supplementary References 1

1. Dellon ES, Liacouras CA. Advances in clinical management of eosinophilic esophagitis. *Gastroenterology* 2014; 147:1238–1254.
2. Dranove JE, Horn DS, Davis MA, et al. Predictors of response to proton pump inhibitor therapy among children with significant esophageal eosinophilia. *J Pediatr* 2009;154:96–100.
3. Ngo P, Furuta GT, Antonioli DA, Fox VL. Eosinophils in the esophagus—peptic or allergic eosinophilic esophagitis? Case series of three patients with esophageal eosinophilia. *Am J Gastroenterol* 2006; 101:1666–1670.
4. Sayej WN, Patel R, Baker RD, et al. Treatment with high-dose proton pump inhibitors helps distinguish eosinophilic esophagitis from noneosinophilic esophagitis. *J Pediatr Gastroenterol Nutr* 2009;49:393–399.
5. Dohil R, Newbury RO, Aceves S. Transient PPI responsive esophageal eosinophilia may be a clinical subphenotype of pediatric eosinophilic esophagitis. *Dig Dis Sci* 2012;57:1413–1419.
6. Schroeder S, Capocelli KE, Masterson JC, et al. Effect of proton pump inhibitor on esophageal eosinophilia. *J Pediatr Gastroenterol Nutr* 2013;56:166–172.
7. Rea F, Caldaro T, Tambucci R, et al. Eosinophilic esophagitis: is it also a surgical disease? *J Pediatr Surg* 2013;48:304–308.
8. Gutierrez-Junquera C, Fernandez-Fernandez S, Cilleruelo ML, et al. High prevalence of response to proton-pump inhibitor treatment in children with esophageal eosinophilia. *J Pediatr Gastroenterol Nutr* 2016; 62:704–710.
9. Lucendo AJ, Arias A, Molina-Infante J. Efficacy of proton pump inhibitor frugs for inducing clinical and histologic remission in patients with symptomatic esophageal eosinophilia: a systematic review and meta-analysis. *Clin Gastroenterol Hepatol* 2016;14:13–22.e1.
10. DiGiovanni EL, Champeaux AL, Arroyo MR, Richter JE. Esophageal eosinophilia treated with long-duration proton pump inhibitor therapy. *ACG Case Rep J* 2016; 3:95–97.
11. Potter JW, Saeian K, Staff D, et al. Eosinophilic esophagitis in adults: an emerging problem with unique esophageal features. *Gastrointest Endosc* 2004;59: 355–361.
12. Nantes Castillejo O, Zozaya J, Jimenez-Perez F, Martinez-Penuela J, Borda F. [Incidence and characteristics of eosinophilic esophagitis in adults]. *An Sist Sanit Navar* 2009;32:227–234.
13. Garrean CP, Gonsalves N, Hirano I. Epidemiologic implications of symptom onset in adults with eosinophilic esophagitis. *Gastroenterology* 2009;136(Suppl 1). AB S1875.
14. Jung YM, Lee HS, Lee DH, et al. [Clinical significance of incidentally detected eosinophilic esophagitis with pathologic review]. *Korean J Gastroenterol* 2010;55: 162–168.
15. Abe Y, Iijima K, Ohara S, et al. A Japanese case series of 12 patients with esophageal eosinophilia. *J Gastroenterol* 2011;46:25–30.
16. Levy AN, Rahaman SM, Bonis PA, et al. Hiccups as a presenting symptom of eosinophilic esophagitis. *Case Rep Gastroenterol* 2012;6:340–343.
17. Tomomatsu Y, Yoshino J, Inui K, et al. Clinical features of eosinophilic esophagitis: ten Japanese cases. *Dig Endosc* 2013;25:117–124.
18. Lee JH, Kim MJ, Kim JH, et al. Clinical analysis of primary eosinophilic esophagitis. *J Neurogastroenterol Motil* 2013;19:204–209.
19. Lipka S, Muhammad A, Champeaux A, Richter JE. Case report of proton pump inhibitor responsive esophageal eosinophilia: why 2 months of proton pump inhibitors is required. *Dis Esophagus* 2016;29:700–703.
20. Ahn B, Lee DH, Lee CM, et al. [Proton pump inhibitor-responsive esophageal eosinophilia: an overview of cases from one university hospital center]. *Korean J Gastroenterol* 2016;67:178–182.
21. van Rhijn BD, Weijenborg PW, Verheij J, et al. Proton pump inhibitors partially restore mucosal integrity in patients with proton pump inhibitor-responsive esophageal eosinophilia but not eosinophilic esophagitis. *Clin Gastroenterol Hepatol* 2014;12:1815–1823.e2.
22. Mangla S, Goldin AH, Singal G, et al. Endoscopic features and eosinophil density are associated with food impaction in adults with esophageal eosinophilia. *Dig Dis Sci* 2016;61:2578–2584.
23. Dellon ES, Speck O, Woodward K, et al. Clinical and endoscopic characteristics do not reliably differentiate ppi-responsive esophageal eosinophilia and eosinophilic esophagitis in patients undergoing upper endoscopy: a prospective cohort study. *Am J Gastroenterol* 2013; 108:1854–1860.
24. Molina-Infante J, Ferrando-Lamana L, Ripoll C, et al. Esophageal eosinophilic infiltration responds to proton pump inhibition in most adults. *Clin Gastroenterol Hepatol* 2011;9:110–117.
25. Fujiwara Y, Sugawa T, Tanaka F, et al. A multicenter study on the prevalence of eosinophilic esophagitis and PPI-responsive esophageal eosinophilic infiltration. *Intern Med* 2012;51:3235–3239.
26. Francis DL, Foxx-Orenstein A, Arora AS, et al. Results of ambulatory pH monitoring do not reliably predict response to therapy in patients with eosinophilic oesophagitis. *Aliment Pharmacol Ther* 2012;35:300–307.
27. Vazquez-Elizondo G, Ngamruengphong S, Khrisna M, et al. The outcome of patients with oesophageal eosinophilic infiltration after an eight-week trial of a proton pump inhibitor. *Aliment Pharmacol Ther* 2013;38: 1312–1319.
28. Martinek J, Strosova A, Stefanova M, et al. Treatment with proton pump inhibitors is effective in a majority of adults patients with eosinophilic esophagitis. *Gastroenterology* 2013;144(Suppl 1):S493.
29. Molina-Infante J, Rivas MD, Hernandez-Alonso M, et al. Proton pump inhibitor-responsive oesophageal eosinophilia correlates with downregulation of eotaxin-3 and Th2 cytokines overexpression. *Aliment Pharmacol Ther* 2014;40:955–965.
30. Gomez-Torrijos E, Garcia-Rodriguez R, Castro-Jimenez A, et al. The efficacy of step-down therapy in

- 2041 adult patients with proton pump inhibitor-responsive  
2042 oesophageal eosinophilia. *Aliment Pharmacol Ther*  
2043 2016;43:534–540.
- 2044 31. Philpott H, Nandurkar S, Royce SG, et al. A prospective  
2045 open clinical trial of a proton pump inhibitor, elimination  
2046 diet and/or budesonide for eosinophilic oesophagitis.  
2047 *Aliment Pharmacol Ther* 2016;43:985–993.
- 2048 32. Peterson KA, Thomas KL, Hilden K, et al. Comparison of  
2049 esomeprazole to aerosolized, swallowed fluticasone for  
2050 eosinophilic esophagitis. *Dig Dis Sci* 2010;55:1313–1319.
- 2051 33. Moawad FJ, Veerappan GR, Dias JA, et al. Randomized  
2052 controlled trial comparing aerosolized swallowed fluti-  
2053 casone to esomeprazole for esophageal eosinophilia. *Am*  
2054 *J Gastroenterol* 2013;108:366–372.
- 2055 34. Liacouras CA, Furuta GT, Hirano I, et al. Eosinophilic  
2056 esophagitis: updated consensus recommendations for  
2057 children and adults. *J Allergy Clin Immunol* 2011;128:  
2058 3–20.e6.
- 2059 35. Dellon ES, Gonsalves N, Hirano I, et al. ACG clinical  
2060 guideline: evidence based approach to the diagnosis and  
2061 management of esophageal eosinophilia and eosinophilic  
2062 esophagitis. *Am J Gastroenterol* 2013;108:679–692.
- 2063 36. Krarup AL, Villadsen GE, Mejlgaard E, et al. Acid hyper-  
2064 sensitivity in patients with eosinophilic oesophagitis.  
2065 *Scand J Gastroenterol* 2010;45:273–281.
- 2066 37. Jiao D, Ishimura N, Maruyama R, et al. Similarities and  
2067 differences among eosinophilic esophagitis, proton-  
2068 pump inhibitor-responsive esophageal eosinophilia, and  
2069 reflux esophagitis: comparisons of clinical, endoscopic,  
2070 and histopathological findings in Japanese patients.  
2071 *J Gastroenterol* 2017;52:203–210.
- 2072 38. Jung DH, Yun GW, Lee YJ, et al. Clinicopathologic  
2073 analysis of proton pump inhibitor-responsive esopha-  
2074 geal eosinophilia in Korean patients. *Gut Liver* 2015;  
2075 10:37–41.
- 2076 39. Molina-Infante J, Rodriguez-Sanchez J, Martinek J, et al.  
2077 Long-term loss of response in proton pump inhibitor-  
2078 responsive esophageal eosinophilia is uncommon and  
2079 influenced by CYP2C19 genotype and rhinoconjunctivi-  
2080 tis. *Am J Gastroenterol* 2015;110:1567–1575.
- 2081 40. Merwat SN, Spechler SJ. Might the use of acid-  
2082 suppressive medications predispose to the develop-  
2083 ment of eosinophilic esophagitis? *Am J Gastroenterol*  
2084 2009;104:1897–1902.
- 2085 41. Spechler SJ, Genta RM, Souza RF. Thoughts on the  
2086 complex relationship between gastroesophageal reflux  
2087 disease and eosinophilic esophagitis. *Am J Gastro-*  
2088 *enterol* 2007;102:1301–1306.
- 2089 42. Orel R, Murch S, Amil Dias J, et al. Eosinophilic esoph-  
2090 agitis that develops during therapy with proton pump  
2091 inhibitors: case series and possible mechanisms. *Acta*  
2092 *Gastroenterol Belg* 2016;79:245–250.
- 2093 43. Kedika RR, Souza RF, Spechler SJ. Potential anti-  
2094 inflammatory effects of proton pump inhibitors: a re-  
2095 view and discussion of the clinical implications. *Dig Dis*  
2096 *Sci* 2009;54:2312–2317.
- 2097 44. Biswas K, Bandyopadhyay U, Chattopadhyay I, et al.  
2098 A novel antioxidant and antiapoptotic role of omeprazole  
2099 to block gastric ulcer through scavenging of hydroxyl  
2100 radical. *J Biol Chem* 2003;278:10993–11001.
- 2101 45. Pastoris O, Verri M, Boschi F, et al. Effects of esome-  
2102 prazole on glutathione levels and mitochondrial oxidative  
2103 phosphorylation in the gastric mucosa of rats treated  
2104 with indomethacin. *Naunyn Schmiedebergs Arch Phar-*  
2105 *macol* 2008;378:421–429.
- 2106 46. Becker JC, Grosser N, Waltke C, et al. Beyond gastric  
2107 acid reduction: proton pump inhibitors induce heme  
2108 oxygenase-1 in gastric and endothelial cells. *Biochem*  
2109 *Biophys Res Commun* 2006;345:1014–1021.
- 2110 47. Lafourcade C, Sobo K, Kieffer-Jaquinod S, et al. Regu-  
2111 lation of the V-ATPase along the endocytic pathway  
2112 occurs through reversible subunit association and  
2113 membrane localization. *PLoS One* 2008;3:e2758.
- 2114 48. Harada M, Shakado S, Sakisaka S, et al. Bafilomycin A1,  
2115 a specific inhibitor of V-type H<sup>+</sup>-ATPases, inhibits the  
2116 acidification of endocytic structures and inhibits horse-  
2117 radish peroxidase uptake in isolated rat sinusoidal  
2118 endothelial cells. *Liver* 1997;17:244–250.
- 2119 49. Suzuki M, Mori M, Miura S, et al. Omeprazole attenuates  
2120 oxygen-derived free radical production from human  
2121 neutrophils. *Free Radic Biol Med* 1996;21:727–731.
- 2122 50. Wandall JH. Effects of omeprazole on neutrophil chemo-  
2123 taxis, super oxide production, degranulation, and trans-  
2124 location of cytochrome b-245. *Gut* 1992;33:617–621.
- 2125 51. Zedtwitz-Liebenstein K, Wenisch C, Patruta S, et al.  
2126 Omeprazole treatment diminishes intra- and extracellular  
2127 neutrophil reactive oxygen production and bactericidal  
2128 activity. *Crit Care Med* 2002;30:1118–1122.
- 2129 52. Handa O, Yoshida N, Fujita N, et al. Molecular mecha-  
2130 nisms involved in anti-inflammatory effects of proton  
2131 pump inhibitors. *Inflamm Res* 2006;55:476–480.
- 2132 53. Suzuki M, Nakamura M, Mori M, et al. Lansoprazole in-  
2133 hibits oxygen-derived free radical production from neu-  
2134 trophils activated by *Helicobacter pylori*. *J Clin*  
2135 *Gastroenterol* 1995;20(Suppl 2):S93–S96.
- 2136 54. Martins de Oliveira R, Antunes E, Pedrazzoli J Jr,  
2137 Gambero A. The inhibitory effects of H<sup>+</sup> K<sup>+</sup> ATPase  
2138 inhibitors on human neutrophils in vitro: restoration by a  
2139 K<sup>+</sup> ionophore. *Inflamm Res* 2007;56:105–111.
- 2140 55. Kurashima K, Numata M, Yachie A, et al. The role of  
2141 vacuolar H<sup>(+)</sup>-ATPase in the control of intragranular pH and  
2142 exocytosis in eosinophils. *Lab Invest* 1996;75:689–698.
- 2143 56. Kottyan LC, Collier AR, Cao KH, et al. Eosinophil viability  
2144 is increased by acidic pH in a cAMP- and GPR65-  
2145 dependent manner. *Blood* 2009;114:2774–2782.
- 2146 57. Barthel SR, Annis DS, Mosher DF, Johansson MW.  
2147 Differential engagement of modules 1 and 4 of  
2148 vascular cell adhesion molecule-1 (CD106) by  
2149 integrins alpha4beta1 (CD49d/29) and alphaMbeta2  
2150 (CD11b/18) of eosinophils. *J Biol Chem* 2006;  
2151 281:32175–32187.
- 2152 58. Sasaki T, Yamaya M, Yasuda H, et al. The proton pump  
2153 inhibitor lansoprazole inhibits rhinovirus infection in  
2154 cultured human tracheal epithelial cells. *Eur J Pharmacol*  
2155 2005;509:201–210.
- 2156 59. Rothenberg ME. Molecular, genetic, and cellular bases  
2157 for treating eosinophilic esophagitis. *Gastroenterology*  
2158 2015;148:1143–1157.
- 2159 60. Cheng E, Zhang X, Huo X, et al. Omeprazole blocks  
2160 eotaxin-3 expression by oesophageal squamous cells

- 2161 from patients with eosinophilic oesophagitis and GORD. 2221  
 2162 Gut 2013;62:824–832. 2222  
 2163 61. Zhang X, Cheng E, Huo X, et al. Omeprazole blocks 2223  
 2164 STAT6 binding to the eotaxin-3 promoter in eosinophilic 2224  
 2165 esophagitis cells. PLoS One 2012;7:e50037. 2225  
 2166 62. Blanchard C, Stucke EM, Burwinkel K, et al. Coordinate 2226  
 2167 interaction between IL-13 and epithelial differentiation 2227  
 2168 cluster genes in eosinophilic esophagitis. J Immunol 2228  
 2169 2010;184:4033–4041. 2229  
 2170 63. Min JY, Ocampo CJ, Stevens WW, et al. Proton pump 2230  
 2171 inhibitors decrease eotaxin-3/CCL26 expression in pa- 2231  
 2172 tients with chronic rhinosinusitis with nasal polyps: 2232  
 2173 possible role of the nongastric H,K-ATPase. J Allergy 2233  
 2174 Clin Immunol 2017;139:130–141.e11. 2234  
 2175 64. Tobey NA, Carson JL, Alkiek RA, Orlando RC. Dilated 2235  
 2176 intercellular spaces: a morphological feature of acid 2236  
 2177 reflux—damaged human esophageal epithelium. 2237  
 2178 Gastroenterology 1996;111:1200–1205. 2238  
 2179 65. Tobey NA, Hosseini SS, Argote CM, et al. Dilated inter- 2239  
 2180 cellular spaces and shunt permeability in nonerosive 2240  
 2181 acid-damaged esophageal epithelium. Am J Gastro- 2241  
 2182 enterol 2004;99:13–22. 2242  
 2183 66. Tobey NA, Gambling TM, Vanegas XC, et al. Physico- 2243  
 2184 chemical basis for dilated intercellular spaces in non- 2244  
 2185 erosive acid-damaged rabbit esophageal epithelium. 2245  
 2186 Dis Esophagus 2008;21:757–764. 2246  
 2187 67. Dunbar KB, Agoston AT, Odze RD, et al. Association of 2247  
 2188 acute gastroesophageal reflux disease with esophageal 2248  
 2189 histologic changes. JAMA 2016;315:2104–2112. 2249  
 2190 68. Calabrese C, Bortolotti M, Fabbri A, et al. Reversibility of 2250  
 2191 GERD ultrastructural alterations and relief of symptoms 2251  
 2192 after omeprazole treatment. Am J Gastroenterol 2005; 2252  
 2193 100:537–542. 2253  
 2194 69. O’Shea KM, Aceves SS, Dellon ES, et al. Pathophysi- 2254  
 2195 ology of eosinophilic esophagitis. Gastroenterology 2255  
 2196 2018;154:333–345. 2256  
 2197 70. Katzka DA, Ravi K, Geno DM, et al. Endoscopic mucosal 2257  
 2198 impedance measurements correlate with eosinophilia 2258  
 2199 and dilation of intercellular spaces in patients with 2259  
 2200 eosinophilic esophagitis. Clin Gastroenterol Hepatol 2260  
 2201 2015;13:1242–1248.e1. 2261  
 2202 2262  
 2203 2263  
 2204 2264  
 2205 2265  
 2206 2266  
 2207 2267  
 2208 2268  
 2209 2269  
 2210 2270  
 2211 2271  
 2212 2272  
 2213 2273  
 2214 2274  
 2215 2275  
 2216 2276  
 2217 2277  
 2218 2278  
 2219 2279  
 2220 2280
71. Sherrill JD, Kc K, Wu D, et al. Desmoglein-1 regulates 2221  
 esophageal epithelial barrier function and immune re- 2222  
 sponses in eosinophilic esophagitis. Mucosal Immunol 2223  
 2014;7:718–729. 2224  
 72. Warners MJ, van Rhijn BD, Verheij J, et al. Disease ac- 2225  
 tivity in eosinophilic esophagitis is associated with 2226  
 impaired esophageal barrier integrity. Am J Physiol 2227  
 Gastrointest Liver Physiol 2017;313:G230–G238. 2228  
 73. Ishimura N, Ishihara S, Kinoshita Y. Sustained acid 2229  
 suppression by potassium-competitive acid blocker 2230  
 (P-CAB) may be an attractive treatment candidate for 2231  
 patients with eosinophilic esophagitis. Am J Gastro- 2232  
 enterol 2016;111:1203–1204. 2233  
 74. Squires KA, Cameron DJ, Oliver M, da Fonseca 2234  
 Junqueira JC. Herpes simplex and eosinophilic oeso- 2235  
 phagitis: the chicken or the egg? J Pediatr Gastroenterol 2236  
 Nutr 2009;49:246–250. 2237  
 75. Zimmermann D, Criblez DH, Dellon ES, et al. acute 2238  
 herpes simplex viral esophagitis occurring in 5 immu- 2239  
 nocompetent individuals with eosinophilic esophagitis. 2240  
 ACG Case Rep J 2016;3:165–168. 2241  
 76. Homan M, Orel R, Liacouras C. Caustic ingestion: a 2242  
 possible cause of eosinophilic esophagitis? Pediatrics 2243  
 2013;131:e1284–e1287. 2244  
 77. Halsey KD, Arora M, Bulsiewicz WJ, et al. Eosinophilic 2245  
 infiltration of the esophagus following endoscopic ablation 2246  
 of Barrett’s neoplasia. Dis Esophagus 2013;26:113–116. 2247  
 78. Freedberg DE, Kim LS, Yang YX. the risks and benefits of 2248  
 long-term use of proton pump inhibitors: expert review and 2249  
 best practice advice from the American Gastroenterolog- 2250  
 ical Association. Gastroenterology 2017;152:706–715. 2251  
 79. Krishnan U, Mousa H, Dall’Oglio L, et al. ESPGHAN- 2252  
 NASPGHAN guidelines for the evaluation and treatment 2253  
 of gastrointestinal and nutritional complications in chil- 2254  
 dren with esophageal atresia-tracheoesophageal fistula. 2255  
 J Pediatr Gastroenterol Nutr 2016;63:550–570. 2256  
 80. Rosen R, Amirault J, Liu H, et al. Changes in gastric and 2257  
 lung microflora with acid suppression: acid suppression 2258  
 and bacterial growth. JAMA Pediatr 2014;168:932–937. 2259  
 81. Yadlapati R, Kahrilas PJ. When is proton pump inhibitor 2260  
 use appropriate? BMC Med 2017;15:36. 2261  
 2262  
 2263  
 2264  
 2265  
 2266  
 2267  
 2268  
 2269  
 2270  
 2271  
 2272  
 2273  
 2274  
 2275  
 2276  
 2277  
 2278  
 2279  
 2280

## Supplementary Materials 3

### Potential Ways to Evaluate for the Contribution of GERD and Distinguish Between GERD and EoE in Patients With Esophageal Eosinophilia

**The Sensitivity and Specificity of Diagnostic Tests for GERD.** GERD is defined as a condition that develops when the reflux of stomach contents causes troublesome symptoms and/or complications.<sup>1</sup> The lack of a criterion standard for the diagnosis of GERD makes attempts at defining the accuracy of any individual test problematic. Composite definitions of GERD using a combination of reflux esophagitis, abnormal pH testing results, symptom association probability metrics, and symptom response to PPI therapy have reported 42%–65% sensitivity and 70% specificity for validated symptom instruments for the diagnosis of GERD.<sup>2</sup> Endoscopic features of GERD have a sensitivity of approximately 50% and specificity of 95%.<sup>3</sup> pH testing has a sensitivity of 65%–90%<sup>4,5</sup> and a high degree of specificity that varies based on the specific symptom being assessed. Histologic features of basal zone hyperplasia, papillary elongation, inflammatory cell infiltrate, and dilated intracellular spaces have widely varying reported sensitivities. Symptom response to PPI therapy is often used in clinical practice, with a reported sensitivity of 71%–78% and specificity of 44%–54%.<sup>2,6</sup>

**The Utility of pH Testing for Esophageal Eosinophilia, PPI-REE, and EoE.** Results of pH testing in patients with esophageal eosinophilia, PPI-REE, and EoE have raised more questions than answers regarding the potential role of GERD in these entities. The conclusions are largely based on retrospectively collected data from select patient cohorts with specific indications for reflux testing. Nevertheless, both pediatric and adult series support the concept that pH testing is more commonly normal in patients with levels of esophageal eosinophilia > 20 eos/hpf.<sup>7–9</sup> Similarly, GERD defined by pH testing is associated with low-grade esophageal eosinophilia.<sup>10</sup> In a small number of series, however, abnormal pH testing has been seen with high-grade esophageal eosinophilia.<sup>11</sup> Furthermore, the data from studies focusing on patients with esophageal eosinophilia suggests that a histologic response to PPI is more common among patients with abnormal pH testing.

**What Is the Utility of Endoscopy for Differentiating PPI-REE and EoE?** Studies reporting endoscopic findings in patients with PPI-REE and EoE identified endoscopic features of EoE (rings, furrows, exudate, stricture) more commonly in EoE than PPI-REE, but these did not persist after multivariable analysis.<sup>12</sup> Endoscopic features of hiatus hernia, reflux esophagitis, and Barrett's esophagus have been described in patients with both EoE and PPI-REE. Although the inclusion criteria in the reported studies were less restrictive than the studies reporting pH monitoring, most studies were again retrospective and did not use validated endoscopic scoring tools for either EoE or GERD.

**Alternative Approaches That Might Distinguish EoE From GERD.** *Histology.* A proportion of patients with severe GERD do show eosinophils in the mucosal inflammation, but usually in small numbers (1–3/hpf), and these

resolve with PPI therapy.<sup>13</sup> Based on available data, neither histopathology nor distribution of inflammatory changes in esophageal biopsy specimens accurately predicts response to PPI therapy. Molina-Infante identified a GERD-like group of adults with lower-grade eosinophil counts (15–35 eos/hpf), with a high rate of clinical symptoms of GERD (35% heartburn as major complaint) and endoscopic GERD (60%), and pathologic pH monitoring in the remaining 40%.<sup>14</sup> Histologic response to PPIs was 100% in this subgroup compared with 50% among patients with a higher degree of eosinophilia and an EoE phenotype.

Collins et al have defined a recent system to evaluate EoE by histology, named the Eosinophilic Esophagitis Histology Scoring System (EoEHSS).<sup>15</sup> Based on a single study, the EoEHSS provided a more comprehensive examination of multiple histologic features of EoE and outperformed eosinophil density as a histologic activity measure. Further studies will determine if this system can discriminate EoE from PPI-REE and GERD.

*Histology Biomarkers.* Positive ALOX15 immunoprecipitation is more prevalent in EoE than in GERD and may prove to be a useful diagnostic marker in patients with discrepant biopsy findings between the proximal and distal esophagus.<sup>16</sup> Regulatory T cells in esophageal tissue are significantly more numerous in EoE compared with GERD.<sup>17</sup> More activated mast cells are present in the esophageal mucosa in patients with EoE vs GERD.<sup>18–21</sup> In addition, eotaxin-3 immunostaining is significantly higher in EoE compared with GERD.<sup>21–23</sup> Numbers of eosinophils and degranulation could be underestimated by hematoxylin and eosin staining, and eosinophil-myelin basic protein immunoreactivity is helpful to distinguish GERD and EoE.<sup>21,22,24</sup>

*Mucosal Impedance.* Recently, a minimally invasive device was developed to detect mucosal impedance as a measure of epithelial integrity during endoscopy. This device can measure alternation in esophageal epithelium due to GERD and EoE and is capable of distinguishing the 2 from each other and from normal epithelium with high confidence.<sup>25</sup> Mucosal impedance measurements correlate inversely with eosinophil counts (ie, lower impedance correlates with higher eosinophil counts).<sup>26</sup> Unlike GERD, for which the values are lower in the distal esophagus and recover in the mid and proximal regions, in EoE the values are low all along the esophagus.

*Genetic Testing.* A molecular diagnostic panel based on gene expression in mucosal biopsy samples distinguishes EoE and GERD (Wen 2013).<sup>27</sup> A PPI-REE transcriptome study<sup>28</sup> a recent genome-wide analysis<sup>29</sup> directly showed an overlapping transcriptome between EoE and PPI-REE. There is only a marginal difference between the 2 entities, with a gene for a potassium channel (Kir2.1, *KNJ2*) being potentially differentially expressed. Studies comparing the genetic signature of biopsy samples from patients with EoE, GERD, and PPI-REE that have similar numbers of intraepithelial eosinophils will be helpful to determine if the etiology of mucosal eosinophilia can be identified in biopsy samples containing  $\geq 15$  eos/hpf.

*High-Resolution Manometry.* Studies have identified early pan-esophageal pressurization and compartmentalized pressurization in 16%–48% of adult EoE patients and rarely in GERD control individuals.<sup>30</sup> Savarino and colleagues analyzed data on 35 EoE, 17 PPI-REE, and 27 GERD patients.<sup>31</sup> PPI-REE and GERD patients had similar frequency of heartburn/acid regurgitation symptoms and esophagitis that were statistically different from those of EoE patients. Manometric features of GERD including lower esophageal sphincter basal pressure and type 2–3 esophagogastric junction morphology were significantly more common in PPI-REE than EoE.

**Challenges Created by the Background Prevalence of GERD.** GERD is an extremely common disorder (prevalence, 10%–20% in the United States and Europe).<sup>1</sup> This high background prevalence confounds attempts to clearly differentiate EoE from GERD. Furthermore, the high background prevalence of GERD likely leads to an underestimation of the true prevalence of PPI-REE, although the magnitude of this underestimation is unclear. These data suggest that even in patients with dysphagia, GERD is many times more common than PPI-REE.

### Supplementary References 3

1. Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. *Am J Gastroenterol* 2006;101:1900–1920.
2. Dent J, Vakil N, Jones R, et al. Accuracy of the diagnosis of GORD by questionnaire, physicians and a trial of proton pump inhibitor treatment: the Diamond Study. *Gut* 2010;59:714–721.
3. Muthusamy VR, Lightdale JR, Acosta RD, et al. The role of endoscopy in the management of GERD. *Gastrointest Endosc* 2015;81:1305–1310.
4. Jamieson JR, Stein HJ, DeMeester TR, et al. Ambulatory 24-h esophageal pH monitoring: normal values, optimal thresholds, specificity, sensitivity, and reproducibility. *Am J Gastroenterol* 1992;87:1102–1111.
5. Ayazi S, Lipham JC, Portale G, et al. Bravo catheter-free pH monitoring: normal values, concordance, optimal diagnostic thresholds, and accuracy. *Clin Gastroenterol Hepatol* 2009;7:60–67.
6. Numans ME, Lau J, de Wit NJ, Bonis PA. Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics. *Ann Intern Med* 2004;140:518–527.
7. Attwood SE, Smyrk TC, Demeester TR, Jones JB. Esophageal eosinophilia with dysphagia. A distinct clinicopathologic syndrome. *Dig Dis Sci* 1993;38:109–116.
8. Liacouras CA, Wenner WJ, Brown K, Ruchelli E. Primary eosinophilic esophagitis in children: successful treatment with oral corticosteroids. *J Pediatr Gastroenterol Nutr* 1998;26:380–385.
9. Steiner SJ, Gupta SK, Croffie JM, Fitzgerald JF. Correlation between number of eosinophils and reflux index on same day esophageal biopsy and 24 hour esophageal pH monitoring. *Am J Gastroenterol* 2004;99:801–805.

10. Fiocca R, Mastracci L, Engstrom C, et al. Long-term outcome of microscopic esophagitis in chronic GERD patients treated with esomeprazole or laparoscopic antireflux surgery in the LOTUS trial. *Am J Gastroenterol* 2010;105:1015–1023.
11. Rodrigo S, Abboud G, Oh D, et al. High intraepithelial eosinophil counts in esophageal squamous epithelium are not specific for eosinophilic esophagitis in adults. *Am J Gastroenterol* 2008;103:435–442.
12. Dellon ES, Speck O, Woodward K, et al. Clinical and endoscopic characteristics do not reliably differentiate PPI-responsive esophageal eosinophilia and eosinophilic esophagitis in patients undergoing upper endoscopy: a prospective cohort study. *Am J Gastroenterol* 2013;108:1854–1860.
13. Yerian L, Fiocca R, Mastracci L, et al. Refinement and reproducibility of histologic criteria for the assessment of microscopic lesions in patients with gastroesophageal reflux disease: the Esohisto Project. *Dig Dis Sci* 2011;56:2656–2665.
14. Molina-Infante J, Ferrando-Lamana L, Ripoll C, et al. Esophageal eosinophilic infiltration responds to proton pump inhibition in most adults. *Clin Gastroenterol Hepatol* 2011;9:110–117.
15. Collins MH, Martin LJ, Alexander ES, et al. Newly developed and validated eosinophilic esophagitis histology scoring system and evidence that it outperforms peak eosinophil count for disease diagnosis and monitoring. *Dis Esophagus* 2017;30:1–8.
16. Matoso A, Allen D, Herzlinger M, et al. Correlation of ALOX15 expression with eosinophilic or reflux esophagitis in a cohort of pediatric patients with esophageal eosinophilia. *Hum Pathol* 2014;45:1205–1212.
17. Fuentebella J, Patel A, Nguyen T, et al. Increased number of regulatory T cells in children with eosinophilic esophagitis. *J Pediatr Gastroenterol Nutr* 2010;51:283–289.
18. Kirsch R, Bokhary R, Marcon MA, Cutz E. Activated mucosal mast cells differentiate eosinophilic (allergic) esophagitis from gastroesophageal reflux disease. *J Pediatr Gastroenterol Nutr* 2007;44:20–26.
19. Sridhara S, Ravi K, Smyrk TC, et al. Increased numbers of eosinophils, rather than only etiology, predict histologic changes in patients with esophageal eosinophilia. *Clin Gastroenterol Hepatol* 2012;10:735–741.
20. Dellon ES, Chen X, Miller CR, et al. Tryptase staining of mast cells may differentiate eosinophilic esophagitis from gastroesophageal reflux disease. *Am J Gastroenterol* 2011;106:264–271.
21. Dellon ES, Speck O, Woodward K, et al. Markers of eosinophilic inflammation for diagnosis of eosinophilic esophagitis and proton pump inhibitor-responsive esophageal eosinophilia: a prospective study. *Clin Gastroenterol Hepatol* 2014;12:2015–2022.
22. Dellon ES, Chen X, Miller CR, et al. Diagnostic utility of major basic protein, eotaxin-3, and leukotriene enzyme staining in eosinophilic esophagitis. *Am J Gastroenterol* 2012;107:1503–1511.
23. Moawad FJ, Wells JM, Johnson RL, et al. Comparison of eotaxin-3 biomarker in patients with eosinophilic

2461  
2462  
2463  
2464  
2465  
2466  
2467  
2468  
2469  
2470  
2471  
2472  
2473  
2474  
2475  
2476  
2477  
2478  
2479  
2480  
2481  
2482  
2483  
2484  
2485  
2486  
2487  
2488  
2489  
2490  
2491  
2492  
2493  
2494  
2495  
2496  
2497  
2498  
2499  
2500  
2501  
2502  
2503  
2504  
2505  
2506  
2507  
2508  
2509  
2510  
2511  
2512  
2513  
2514  
2515  
2516  
2517  
2518  
2519  
2520

- oesophagitis, proton pump inhibitor-responsive oesophageal eosinophilia and gastro-oesophageal reflux disease. *Aliment Pharmacol Ther* 2015;42:231–238.
24. Mueller S, Aigner T, Neureiter D, Stolte M. Eosinophil infiltration and degranulation in oesophageal mucosa from adult patients with eosinophilic oesophagitis: a retrospective and comparative study on pathological biopsy. *J Clin Pathol* 2006;59:1175–1180.
25. Ates F, Yuksel ES, Higginbotham T, et al. Mucosal impedance discriminates GERD from non-GERD conditions. *Gastroenterology* 2015;148:334–343.
26. Katzka DA, Ravi K, Geno DM, et al. Endoscopic mucosal impedance measurements correlate with eosinophilia and dilation of intercellular spaces in patients with eosinophilic esophagitis. *Clin Gastroenterol Hepatol* 2015;13:1242–1248.e1.
27. Wen T, Stucke EM, Grotjan TM, et al. Molecular diagnosis of eosinophilic esophagitis by gene expression profiling. *Gastroenterology* 2013;145:1289–1299.
28. Wen T, Dellon ES, Moawad FJ, et al. Transcriptome analysis of proton pump inhibitor-responsive esophageal eosinophilia reveals proton pump inhibitor-reversible allergic inflammation. *J Allergy Clin Immunol* 2015;135:187–197.
29. Shoda T, Matsuda A, Nomura I, et al. Eosinophilic esophagitis versus proton pump inhibitor-responsive esophageal eosinophilia: transcriptome analysis. *J Allergy Clin Immunol* 2017;139:2010–2013.e4.
30. Roman S, Hirano I, Kwiatek MA, et al. Manometric features of eosinophilic esophagitis in esophageal pressure topography. *Neurogastroenterol Motil* 2011;23:208–214.e111.
31. Savarino EV, Tolone S, Bartolo O, et al. The GerdQ questionnaire and high resolution manometry support the hypothesis that proton pump inhibitor-responsive oesophageal eosinophilia is a GERD-related phenomenon. *Aliment Pharmacol Ther* 2016;44:522–530.

UNCORRECTED PROOF